US20120141503A1 - Heavy Chain and Domain Antibodies - Google Patents
Heavy Chain and Domain Antibodies Download PDFInfo
- Publication number
- US20120141503A1 US20120141503A1 US13/355,981 US201213355981A US2012141503A1 US 20120141503 A1 US20120141503 A1 US 20120141503A1 US 201213355981 A US201213355981 A US 201213355981A US 2012141503 A1 US2012141503 A1 US 2012141503A1
- Authority
- US
- United States
- Prior art keywords
- heavy chain
- vhh
- fragments
- rotavirus
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012634 fragment Substances 0.000 claims abstract description 141
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 71
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000013604 expression vector Substances 0.000 claims abstract description 18
- 241000186660 Lactobacillus Species 0.000 claims description 135
- 244000005700 microbiome Species 0.000 claims description 83
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 78
- 241000702670 Rotavirus Species 0.000 claims description 69
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 61
- 229940039696 lactobacillus Drugs 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 27
- 238000002560 therapeutic procedure Methods 0.000 claims description 21
- 244000199866 Lactobacillus casei Species 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 238000011321 prophylaxis Methods 0.000 claims description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 8
- 229940017800 lactobacillus casei Drugs 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 206010039231 Rotaviral infections Diseases 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 79
- 235000013305 food Nutrition 0.000 abstract description 49
- 229940072221 immunoglobulins Drugs 0.000 abstract description 45
- 238000012384 transportation and delivery Methods 0.000 abstract description 35
- 208000015181 infectious disease Diseases 0.000 abstract description 29
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract description 23
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract description 23
- 238000007726 management method Methods 0.000 abstract description 22
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 18
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000000047 product Substances 0.000 description 51
- 235000002198 Annona diversifolia Nutrition 0.000 description 45
- 244000303258 Annona diversifolia Species 0.000 description 42
- 206010012735 Diarrhoea Diseases 0.000 description 41
- 241000894006 Bacteria Species 0.000 description 33
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 28
- 241000700605 Viruses Species 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 26
- 230000000369 enteropathogenic effect Effects 0.000 description 24
- 230000000529 probiotic effect Effects 0.000 description 23
- 206010067470 Rotavirus infection Diseases 0.000 description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 239000006041 probiotic Substances 0.000 description 22
- 235000018291 probiotics Nutrition 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 235000013616 tea Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 241001122767 Theaceae Species 0.000 description 20
- 210000002784 stomach Anatomy 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 241000186605 Lactobacillus paracasei Species 0.000 description 19
- 239000003925 fat Substances 0.000 description 19
- 235000019197 fats Nutrition 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 230000002953 anti-rotaviral effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002955 isolation Methods 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000007407 health benefit Effects 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 12
- 235000015243 ice cream Nutrition 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 235000015071 dressings Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000013310 margarine Nutrition 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000251730 Chondrichthyes Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 235000015092 herbal tea Nutrition 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000003264 margarine Substances 0.000 description 6
- 239000008268 mayonnaise Substances 0.000 description 6
- 235000010746 mayonnaise Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 241000282832 Camelidae Species 0.000 description 5
- 206010017918 Gastroenteritis viral Diseases 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000702646 Rhesus rotavirus Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000025171 antigen binding proteins Human genes 0.000 description 4
- 108091000831 antigen binding proteins Proteins 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000003022 colostrum Anatomy 0.000 description 4
- 235000021277 colostrum Nutrition 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241001134770 Bifidobacterium animalis Species 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 241000282838 Lama Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000010410 calcium alginate Nutrition 0.000 description 3
- 239000000648 calcium alginate Substances 0.000 description 3
- 229960002681 calcium alginate Drugs 0.000 description 3
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 colourants Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000008821 health effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000012933 kinetic analysis Methods 0.000 description 3
- 235000015122 lemonade Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108010056511 proteinase P Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 235000011888 snacks Nutrition 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108700012261 Rotavirus VP7 Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000000135 prohibitive effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960002181 saccharomyces boulardii Drugs 0.000 description 2
- 235000014438 salad dressings Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 238000012232 AGPC extraction Methods 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241001328122 Bacillus clausii Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000702673 Bovine rotavirus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710090058 Conjugated bile acid hydrolase Proteins 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- 241000702192 Escherichia virus P2 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039555 Galectin-7 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 1
- 101000648395 Homo sapiens Mitochondrial import receptor subunit TOM70 Proteins 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
- 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 1
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 1
- 235000004050 Lactobacillus casei DN 114001 Nutrition 0.000 description 1
- 240000006030 Lactobacillus casei DN 114001 Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 241000212468 Lactobacillus plantarum 80 Species 0.000 description 1
- 244000185256 Lactobacillus plantarum WCFS1 Species 0.000 description 1
- 235000011227 Lactobacillus plantarum WCFS1 Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 102100028811 Mitochondrial import receptor subunit TOM70 Human genes 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241000369774 Norwalk-like virus Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000202223 Oenococcus Species 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241001452677 Ogataea methanolica Species 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000186334 Propionibacterium freudenreichii subsp. shermanii Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000235403 Rhizomucor miehei Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150014136 SUC2 gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241000222124 [Candida] boidinii Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 101150078331 ama-1 gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009937 brining Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013572 fruit purees Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011078 in-house production Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229960005050 live attenuated rota virus Drugs 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 101150044854 repA gene Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000011867 sweet spreads Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/60—Salad dressings; Mayonnaise; Ketchup
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/195—Proteins from microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Definitions
- the present invention relates to heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof suitable for use in the management of infections by enteropathogenic micro-organisms.
- the present invention also relates to a delivery system comprising these heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and hosts comprising expression vectors encoding for these heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof.
- the invention further relates to food products or pharmaceutical preparations comprising a delivery system for delivering antibodies to the gastro-intestinal tract (GIT) wherein the antibodies are active in the gut.
- GIT gastro-intestinal tract
- Immunoglobulins are glycoproteins, which specifically recognise foreign molecules. These recognised foreign molecules are called antigens. When antigens invade humans or animals, an immunological response is triggered which involves the production of antibodies by B-lymphocytes. By this immunological response, microorganisms, larger parasites, viruses and bacterial toxins can be rendered harmless.
- IgGs are the most abundant immunoglobulins in the blood. They have a basic structure of two identical heavy (H) chain polypeptides and two identical light (L) chain polypeptides. The H and L chains are kept together by disulfide bridges and non-covalent bonds. The chains themselves can be divided in variable and constant domains.
- the variable domains of the heavy and light chain (VH and VL) which are extremely variable in amino acid sequences are located at the N-terminal part of the antibody molecule. VH and VL together form the unique antigen-recognition site.
- the amino acid sequences of the remaining C-terminal domains are much less variable and are called CH1, CH2, CH3 and CL.
- the non-antigen binding part of an antibody molecule is called the constant domain Fc and mediates several immunological functions, such as binding to receptors on target cells and complement fixation.
- the unique antigen-binding site of an antibody consists of the heavy and light chain variable domains (VH and VL). Each domain contains four framework regions (FR) and three regions called CDRs (complementarity determining regions) or hypervariable regions. The CDRs strongly vary in sequence and determine the specificity of the antibody. VL and VH domains together form a binding site, which binds a specific antigen.
- Fab fragments are the antigen-binding domains of an antibody molecule.
- Fab fragments can be prepared by papain digestions of whole antibodies.
- Fv fragments are the minimal fragment ( ⁇ 30 kDa) that still contains the whole antigen-binding site of a whole IgG antibody.
- Fv fragments are composed of both the variable heavy chain (VH) and variable light chain (VL) domains. This heterodimer, called Fv fragment (for fragment variable) is still capable of binding the antigen.
- Heavy chain antibodies constitute about one fourth of the IgG antibodies produced by the camelids, e.g. camels and llamas (Hamers-Casterman C., et al. (1993)). These antibodies are formed by two heavy chains but are devoid of light chains. As a consequence, the variable antigen binding part is referred to as the VHH domain and it represents the smallest naturally occurring, intact, antigen-binding site, being only around 120 amino acids in length (Desmyter, A., et al. (2001)). Heavy chain antibodies with a high specificity and affinity can be generated against a variety of antigens through immunization (van der Linden, R. H., et al.
- VHH portion can be readily cloned and expressed in yeast (Frenken, L. G. J., et al. (2000)). Their levels of expression, solubility and stability are significantly higher than those of classical F(ab) or Fv fragments (Ghahroudi, M. A. et al. (1997)). Sharks have also been shown to have a single VH-like domain in their antibodies termed VNAR. (Nuttall et al. (2003)); (Dooley et al. (2003)); (Nuttall et al. (2004)).
- DAbs antigen-binding fragments which comprise only the VH or VL domain of an antibody and are consequently smaller than, for example, Fab and scFv.
- DAbs are the smallest known antigen-binding fragments of antibodies, ranging from 11 kDa to 15 kDa. They are highly expressed in microbial cell culture. Each dAb contains three of the six naturally occurring complementarity determining regions (CDRs) from an antibody.
- Lactobacilli have been investigated with regards to their anti-diarrhoeal properties since the 1960's (Beck, C., et al. Beneficial effects of administration of Lactobacillus acidophilus in diarrhoeal and other intestinal disorders. Am. J. Gastroenterol (1961) 35, 522-30). A limited number of recent controlled trials have shown that certain strains of lactobacilli may have therapeutic as well as prophylactic properties in acute viral gastroenteritis (Mastretta, E., et al. Effect of Lactobacillus CG and breast-feeding in the prevention of rotavirus nosocomial infection. J. Pediatr. Gastroenterol. Nutr. (2002) 35, 527-531). Selected strains of Lactobacillus casei and Lactobacillus plantarum have also been shown to exert strong adjuvant effects on the mucosal and the systemic immune response.
- Lactobacilli are well-known bacteria applied in the production of food products.
- yogurt is normally made by fermenting milk with among others a Lactobacillus strain.
- the fermented acidified product, still containing the viable Lactobacillus is then cooled and consumed at the desired moment.
- Lactobacillus in food products is in the production of meat products for example sausages.
- the Lactobacillus is added to the meat mass prior to applying the casing, followed by a period of ripening in which the fermentation process takes place.
- Lactobacillus in the production of food products is the brining of vegetables such as cabbage (sauerkraut), carrots, olives or beets.
- the natural fermentation process can be controlled by the addition of an appropriate Lactobacillus starter culture.
- Lactobacillus in food products is often associated with several health effects, see for example A. C. Ouwehand et al. in Int. Dairy Journal 8 (1998) 749-758.
- the application of products is associated with several health effects for example relating to gut well being such as IBS (Irritable Bowel Syndrome), reduction of lactose maldigestion, clinical symptoms of diarrhoea, immune stimulation, anti-tumour activity and enhancement of mineral uptake.
- WO 99/23221 discloses multivalent antigen binding proteins for inactivating phages.
- the hosts may be lactic acid bacteria which are used to produce antibody binding fragments which are then harvested and used.
- WO 99/23211 discloses adding the harvested antibody fragments to provide anti-diarrhoea effects.
- WO 00/65057 is directed to the inhibition of viral infection using monovalent antigen-binding proteins.
- the antigen-binding protein may be a heavy chain variable domain derived from an immunoglobulin naturally devoid of light chains, such as those derived from Camelids as described in WO 94/04678.
- WO 00/65057 discloses transforming a host with a gene encoding the monovalent antigen-binding proteins. Suitable hosts can include lactic acid bacteria.
- This disclosure relates to the field of fermentation processing and the problem of phage infection which hampers fermentation. Specifically, llama VHH fragments per se are used to solve the problem of phage infection by neutralising Lactoccoccus lactis bacteriophage P2.
- Both WO 00/65057 and WO 99/23221 involve the use of antibody fragments harvested from a bacterial expression system.
- U.S. Pat. No. 6,605,286 is directed to the use of gram positive bacteria to deliver biologically active polypeptides, such as cytokines, to the body.
- U.S. Pat. No. 6,190,662 and EP 0 848 756 B1 are directed to methods for obtaining surface expression of a desired protein or polypeptide.
- Monedero et al 2004 is directed to in-vitro studies on the use of single-chain antibodies (scFv) expressed by L. casei which recognise the VP8 and fraction of rotavirus outer capsid and blocks rotavirus infection in vitro.
- scFv single-chain antibodies
- Enteropathogenic micro-organisms are micro-organisms which can produce disease in the intestinal tract.
- micro-organisms include E. coli and Salmonella.
- Rotavirus continues to be the single most common cause of infantile diarrhoea in the world and most children get infected during the first 5 years of life. In developing countries, rotavirus induced diarrhoea may cause 600,000 to 870,000 deaths each year and in developed countries, rotavirus disease accounts for immense economic loss. Following the intussusception related withdrawal of the Rhesus rotavirus-tetravalent vaccine in July 1999, several strategies have been employed to try to develop a safe vaccine. Five oral live attenuated rotavirus vaccines are presently undergoing clinical trials for use in children, for example Barnes, G. L. et al. (1997). However, in particular in very young, malnourished children in developing countries the efficacy of such vaccinations might be limited. Several studies have also been conducted using passive immunotherapy, for example Offit, P. A. et al. (1985).
- Secretory immunoglobulins are implicated as a first line of defense against many mucosal pathogens, including rotavirus infection. Protection from clinical disease appears to rely mainly on the production of neutralizing antibodies against the outer capsid proteins VP4 or VP7 (Ruggeri, F. M. at al. (1998)); (Giammarioli, A-M. et al. (1996)). Recently however, non-neutralizing VP6 specific IgA antibodies have also been shown to inhibit rotavirus replication (Feng, N. et al. (2002)); Schwartz-Cornil, I. et al. (2002)).
- the present invention is directed to a new method of therapy and/or prophylaxis of enteropathogenic micro-organisms.
- a delivery system for delivering antibodies to the GIT comprising heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, wherein the immunoglobulins or fragments thereof are active in the gut.
- an expression vector comprising the gene encoding for the heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof.
- a micro-organism preferably Lactobacillus , transformed with the above expression vector.
- a method for delivering antibodies to the gut in the treatment of enteropathogenic micro-organism infections using a micro-organism transformed with the gene encoding for heavy chains immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, comprising the steps of:
- a fifth aspect of the invention there is provided the use of heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, or the delivery system as described above in therapy.
- heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, or the delivery system as described above in the manufacture of a medicament for the treatment of enteropathogenic micro-organism infections, preferably rotaviral infection.
- a method for making a food product or pharmaceutical preparation comprising adding the delivery system to the food product or pharmaceutical preparation during the manufacture of the food product or pharmaceutical preparation.
- FIGS. 1 a and b shows that rotavirus specific VHH particles neutralise rotavirus in-vitro.
- FIG. 2 shows that rotavirus specific VHH particles neutralise rotavirus in-vivo.
- FIG. 3 shows a Map of Lactobacillus expression vectors:
- FIG. 4 a shows the results of Flow cytometry showing the expression of 2A10-scFv (light grey) and VHH1 (dark grey) on the surface of the Lactobacillus paracasei by detection of the E-tag by a mouse anti-E-tag antibody (b) Scanning electron microscope (SEM) picture showing the binding of rotavirus by the VHH1 surface expressing Lactobacillus paracasei.
- FIG. 5 shows in vitro neutralization assay results which test efficacy of lactobacilli expressing VHH1-anchored fragments to inhibit rotavirus infection of MA104 cells. Reduction of infection to 60% or more was considered to be specific neutralization.
- the solid line represents neutralization level achieved by lactobacilli produced E-tag purified VHH1 antibody (20 ⁇ g/ml). Dotted line indicates the neutralization level of 2A10 monoclonal hybridoma supernatant (147 ng/ml). Neutralization achieved by different concentrations of VHH1 anchored lactobacilli ( ⁇ ), 2A10 anchored lactobacilli ( ) and non-transformed lactobacilli ( ⁇ ).
- FIG. 6( a ) shows the prevalence of diarrhoea in mice treated with lactobacilli expressing VHH1-anchored fragments. Pooled results of three experiments (b) Prevalence of diarrhoea in mice treated with lactobacilli surface expressing 2A10-scFv. Pooled results from three experiments.
- FIG. 7 shows duodenum and jejunum sections from pups treated with different formulations, stained with hematoxylin and eosin.
- the bar represents 100 ⁇ m length.
- FIG. 8 shows the load of vp7 RNA in small intestinal tissue samples as determined by real time PCR.
- FIG. 9 shows evaluation of different doses of lactobacilli expressing VHH1-anchored fragments and their efficacy to reduce diarrhea.
- FIG. 10 shows evaluation of lactobacilli expressing VHH1-anchored fragments in a freeze-dried form.
- FIG. 11 shows scanning electron microscope (SEM) picture showing the binding of rotavirus by the VHH1 surface expressing Lactobacillus paracasei.
- FIG. 12 shows an alignment of the VHH's having affinity for Rotavirus viral particles.
- the present invention is directed to the delivery of heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, to the gastro-intestinal tract (GIT) which are suitable for use in the management of infection by enteropathogenic micro-organisms.
- GIT gastro-intestinal tract
- the present invention is also directed to a food product or pharmaceutical composition comprising a delivery system for delivering antibodies to the GIT wherein the antibodies are active in the gut.
- Heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof may be obtained using techniques well known in the art.
- the immunoglobulins or fragments thereof have the following characteristics:
- the heavy chain immunoglobulin or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof are specific to an enteropathogenic micro-organism.
- the antibodies may be llama heavy chain antibodies, more preferably VHH antibodies or fragments thereof.
- VHH antibodies a novel class of IgG antibodies in Camelidae i.e. camels, dromedaries and llamas. (“Naturally occurring antibodies of devoid light-chains” Nature (1993) 363, 446-448).
- Heavy chain antibodies constitute about one fourth of the IgG antibodies produced by the camelids, llamas. These antibodies are formed by two heavy chains but are devoid of light chains.
- the variable antigen binding part is referred to as the VHH domain and it represents the smallest naturally occurring, intact, antigen-binding site (Desmyter, A., et al.
- Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody J. Biol. Chem. (2001) 276, 26285-26290.
- Heavy chain antibodies with a high specificity and affinity can be generated against a variety of antigens and they are readily cloned and expressed in bacteria and yeast (Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae ”. J. Biotechnol. (2000) 78, 11-21). Their levels of expression, solubility and stability are significantly higher than those of classical F(ab) or Fv fragments (Ghahroudi, M. A. et al “Selection and identification of single domain antibody fragments from camel heavy-chain antibodies” FEBS Lett. (1997) 414, 521-526).
- VNAR Single VH-like domain in their antibodies termed VNAR (Nuttall et al. “Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70” Eur. J. Biochem. (2003) 270, 3543-3554; Dooley et al. “Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display” Molecular Immunology (2003) 40, 25-33; Nuttall et al.
- DAbs are the smallest known antigen-binding fragments of antibodies, ranging from 11 kDa to 15 kDa. They are highly expressed in microbial cell culture. Each dAb contains three of the six naturally occurring complementarity determining regions (CDRs) from an antibody.
- CDRs complementarity determining regions
- the immunoglobulin may be multivalent, i.e. bivalent, trivalent, tetravalent, in that it comprises more than one antigen binding site.
- the antigen binding sites may be derived from the same parent antibody or fragment thereof or from different antibodies which bind the same epitope. If all binding sites have the same specificity then a monospecific immunoglobulin is produced. Alternatively a multispecific immunoglobulin may be produced binding to different epitopes of the same antigen or even different antigens.
- immunoglobulin or fragment thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof may be naturally occurring i.e. elicited in vivo upon immunizing an animal with the desired antigen or synthetically made, i.e. obtained by genetic engineering techniques.
- the antibody or fragment thereof may be naturally occurring or may be obtained by genetic engineering using techniques well known in the art.
- the antibody can be chosen to be active against many different antigens, including micro-organisms, larger parasites, viruses and bacterial toxins.
- a functional equivalent means a sequence which shows binding affinity for an antigen similar to the full length sequence.
- additions or deletions of amino acids which do not result in a change of functionality are encompassed by the term functional equivalents.
- a food product or pharmaceutical preparation comprises a delivery system for delivering antibodies to the GIT wherein the antibodies are heavy chain immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and they are active in the gut.
- the delivery system is a micro-organism and the immunoglobulins are llama derived antibodies or fragments thereof.
- these transformed micro-organisms will express llama heavy chain antibodies or fragments thereof on their surface and are able to reduce the viral load, normalize the pathology and mitigate the diarrhoea in an animal model of rotavirus infection.
- the llama heavy chain antibodies or fragments thereof were found to be very effective in reducing infection both in in vitro and in vivo models of rotavirus infection.
- fragments or portions of a whole antibody which can nevertheless exhibit antigen binding affinity is also contemplated.
- Fragments should preferably be functional fragments.
- a functional fragment of a heavy chain means a fragment of a heavy chain of an immunoglobulin which fragment shows binding affinity for an antigen similar to the full length sequence. Binding affinity is present when the dissociation constant is more than 10exp5.
- Such a fragment can be advantageously used in therapy, for example, as it is likely to be less immunogenic and, if needed, is more able to penetrate tissues due to its smaller size.
- the antibodies are suitable for delivery to the GIT and must be able to be active in the stomach and/or gut.
- One advantage of the delivery system of the present invention includes that in vivo production or release of heavy chain immunoglobulin or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach.
- the antibody produced is selected under specific conditions of low pH, preferably from 1.5 to 3.5, and in the presence of pepsin (a protease abundant in the stomach) to result in highly beneficial molecules that work well in the GIT and are suitable for use according to the present invention.
- pepsin a protease abundant in the stomach
- the present application is applicable to the management of enteropathogenic micro-organisms in general.
- the invention is directed to the management of enteropathogenic viruses and/or enteropathogenic bacteria. Management is understood to include therapy and/or prophylaxis.
- Enteropathogenic bacteria may include, for example, Salmonella, Campilobacter, E. coli or Helicobacter .
- Enteropathogenic viruses may include, for example, Norovirus (Norwalk like virus), enteric adenovirus, Coronavirus, astroviruses, caliciviruses, and parvovirus. Rotavirus and the Norwalk family of viruses are the leading causes of viral gastroenteritis, however, a number of other viruses have been implicated in outbreaks. Most preferably, the present invention is directed the management of rotaviral infection.
- the present application may also be used in the management of other non-enteropathogenic viruses like Hepatitis.
- the delivery system may comprise a probiotic micro-organism.
- the probiotic micro-organism should preferably be able to survive passage in the GIT and should be active in the stomach/gut.
- the micro-organism should be able to undergo transient colonization of the GIT; be able to express the gene in the GIT; and be able to stimulate the gut immune system.
- probiotic micro-organisms examples include yeast such as Saccharomyces, Debaromyces, Kluyveromyces and Pichia , moulds such as Aspergillus, Rhizopus, Mucor and Penicillium and bacteria such as the genera Bifidobacterium, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Oenococcus and Lactobacillus.
- yeast such as Saccharomyces, Debaromyces, Kluyveromyces and Pichia
- moulds such as Aspergillus, Rhizopus, Mucor and Penicillium
- bacteria such as the genera Bifidobacterium, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weis
- probiotic micro-organisms are:
- the micro-organism may be a lactic acid bacterium. More, preferably, the micro-organism is chosen from either the genus Lactobacillus or Bifidobacterium . Even more preferably, the micro-organism is Lactobacillus . Particularly, the Lactobacillus is Lactobacillus casei 393 pLZ15. Lactobacillus casei has recently been reidentified as Lactobacillus paracasei (Perez-Martinez, 2003).
- the micro-organism may also be a probiotic Bacillus species, as described in Le H. Duc et al., Applied and Environmental Microbiology, 2004, p. 2161), and particularly preferred are Bacillus cereus, Bacillus clausii and Bacillus pumilus.
- a system based on probiotic bacteria represents a safe and attractive approach and represents one of the cheapest antibodies production systems.
- the wide scale application of the micro-organism, preferably Lactobacillus , expressing antibodies is relatively easy and requires minimal handling and storage costs and economical.
- the micro-organism may be a yeast.
- suitable yeasts include the baker's yeast S. cerevisiae .
- Other yeasts like Candida boidinii, Hansenula polymorpha, Pichia methanolica and Pichia pastoris which are well known systems for the production of heterologous proteins and may be used in the present invention.
- Filamentous fungi in particular species from the genera Trichoderma and Aspergillus have the capacity to secrete large amounts of proteins, metabolites and organic acids into their culture medium. This property has been widely exploited by the food and beverage industries where compounds secreted by these filamentous fungal species have been used for decades.
- micro-organisms may be genetically modified micro-organisms.
- the delivery system will comprise a micro-organism transformed with the gene encoding the heavy chain immunoglobulin or fragment thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof.
- probiotic bacteria are well known in the art and represent one of the cheapest antibodies production systems. Hence, the wide scale application of the lactobacilli expressing antibodies is relatively easy and requires minimal handling and storage costs. Furthermore, the probiotic bacteria are able to colonize the gut at least temporarily, for days, weeks or months, will remain in the gut for longer and enable the constant production of the antibody to enable more constant and prolonged protection against an enteropathogenic microorganism or virus.
- the present invention is based on the findings that heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, of the invention may be used in the therapy or prophylaxis of infection by enteropathogenic micro-organisms.
- immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof may be used in the therapy or prophylaxis of viral gastroenteritis or diarrhoea caused by rotavirus.
- a further advantage of the present invention is that the use of probiotic micro-organisms expressing immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, enables the micro-organism, for example Lactobacillus , to provide the normal health benefits associated with this probiotic micro-organism, together with the prophylactic/therapeutic benefits in the management of the infection to be treated.
- This “dual effect” therapy provides synergistic effects and therefore greater health benefits to the subject than known in the art.
- the heavy chain immunoglobulins or functional fragments thereof of the VHH type are derived from camelids, including llama and camels.
- An alternative source of heavy chain antibodies can be found in sharks. It recently has been shown that sharks also have a single VH-like domain in their antibodies termed VNAR. Fragments of VNAR-type immunoglobulin can be used in accordance with the present invention. Functional equivalents as described before are also contemplated.
- domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof may be used.
- the immunoglobulins are llama derived heavy chain antibodies or fragments thereof.
- Many llama derived heavy chain antibody fragments have been disclosed in the art. More preferred is the heavy chain immunoglobulin or fragment thereof which shows binding affinity with a dissociation constant of at least 10 exp 5 for rotavirus, especially rotavirus strains Wa, CK5, Wa1, RRV or CK5.
- Llama heavy chain antibodies are particularly advantageous as they have surprisingly been found to be very effective in the treatment of rotaviral infection.
- Llama VHH antibody fragments have surprisingly been found to reduce the viral load, normalize the pathology and mitigate diarrhoea during rotavirus infection.
- VHH sequences having affinity of rotavirus are provided by this specification in the sequence listing, SEQ ID No's 1 to 21.
- VHH sequences having at least 70%, 80%, 85%, 90%, 95%, 98% or 99% amino acid identity with SEQ ID No. 1 and having affinity for a rotavirus particle or antigen are also preferred embodiments according to this invention.
- VHH sequences may be derived from camellids, via immunization and/or by screening for affinity, but may also be derived from other mammalian species such as mice or humans and/or be camelized by amino acid substitutions, as described in the art.
- the VHH sequences may be fused to yield multimeric units of 2, 3, 4, 5 or more VHH units, optionally linked via a spacer molecule.
- several VHH sequences may be combined, separately or in one multimeric molecule.
- the VHH sequences have different specificities, for instance VHH sequences may be combined to provide a wide spectrum of affinities for a particular pathogen.
- 2, 3, 4, 5 or more VHH sequences having affinity for any one of rotavirus strains Wa, CK5, Wa1, RRV or CK5 may be combined, as separate monomeric units or as combined units on a carrier, for instance on a probiotic bacterium and/or on a multimeric molecule.
- llama heavy chain antibodies have also unexpectedly been found to be suitable for administration in the GIT.
- Llama heavy chain antibodies were found to be highly resistant to protease degradation in the stomach and to withstand the acidic environment of the stomach. This is despite the fact that the proteolytic system in the GIT is more aggressive an environment than, for example encountered in the mouth. Activity in the gut is hampered by proteolytic activity, including protease and peptidase.
- proteolytic activity including protease and peptidase.
- the present invention is the first system which enables expression of antibodies in the GIT which are suitable for the management of rotavirus infection.
- probiotic micro-organisms When probiotic micro-organisms are chosen as the delivery system, we have found that these transformed micro-organisms will express llama heavy chain antibodies or fragments thereof on their surface and are able to reduce the viral load, normalize the pathology and mitigate the diarrhoea in an animal model of rotavirus infection.
- the llama heavy chain antibodies are then expressed by the micro-organism in the GIT.
- Expression of the llama derived VHH antibody fragment may be both on the surface of the micro-organism and/or as a secreted protein of the micro-organism.
- Preferably secreted forms of the VHH antibody fragment is in multimeric form to enhance aggregation and clearance of the viral load.
- the micro-organism or more preferably a probiotic bacterium is transformed with an expression vector comprising the gene for the llama heavy chain antibody or fragments thereof.
- the expression vector may contain a constitutive promoter in order to express the antibodies or fragments thereof.
- a constitutive promoter will support in situ expression of antibodies by transformed lactobacilli persisting (at least for a short period) in the intestinal tract after administration.
- the promoter may be chosen to be active only in the GIT and/or stomach/gut i.e. suitable for GIT specific expression only. This will ensure expression and/or secretion of the llama heavy chain antibody or fragments thereof in the GIT, preferably the gut.
- the expression vectors described in the examples are able to replicate in the transformed lactobacilli and express the antibodies of fragments thereof. It will be understood that the present invention is not limited to these replication expression vectors only.
- the whole expression cassette can be inserted in a so-called “integration” plasmid, whereby the expression cassette will be integrated into the chromosome of the lactobacilli after transformation, as known in the art (Pouwels, P. H. and Chaillou, S. Gene expression in lactobacilli (2003) Genetics of lactic acid bacteria page 143-188).
- the encapsulation method should survive passage to the stomach through the GIT and should be able to provide a sustained release of the antibody over a set period of time. This will ensure that the llama heavy chain antibody or fragment is delivered over time to the stomach.
- Llama heavy chain antibodies or VHH or VNAR fragments, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, are particularly suitable for this encapsulation method due to their ability to survive in the gut when released.
- delivery of the antibodies to the GIT can be effected by the use of encapsulates, such as those known in the food and pharmaceutical industries. Natural biopolymers may be used. Examples include Ca-alginate, carrageenan, gellan gum or gelatine.
- the delivery system may be an encapsulation method known in the art which will deliver the immunoglobulin or fragments thereof specifically to the gut. The encapsulate must therefore be able to survive until entry to the gut and then be released.
- Such a delivery system comprises a general protective system that protects the antibodies from degradation. Such techniques may include liposome entrapment, spinning disk and coacervation.
- Any trigger can be used to prompt the release of the encapsulated ingredient, such as pH change (enteric coating), mechanical stress, temperature, enzymatic activity.
- enteric coating an enteric coating is used.
- the encapsulation method may allow the slow release of the antibody in the gut and/or stomach. This will enable a constant release of the antibody or functional fragment or equivalent over a set period of time.
- the llama heavy chain antibodies or fragments thereof may be used in the therapy or prophylaxis of viral infection, such as viral gastroenteritis or rotavirus infection.
- the antibodies may be delivered to the GIT using a micro-organism transformed with llama heavy chain antibodies comprising the steps of i) transforming the micro-organism with the gene encoding llama heavy chain antibodies; and ii) administering the transformed micro-organism to the GIT of the human or animal in need of therapy.
- the delivery system may comprise a micro-organism transformed with antibodies or fragments thereof the antibodies are expressed and/or secreted in the gut.
- a micro-organism as the delivery system has the advantages that in vivo production of antibody fragments locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach.
- probiotic bacteria represents a safe and attractive approach to delivering antibodies to the GIT.
- the wide scale application of the lactobacilli expressing antibodies is relatively easy and requires minimal handling and storage costs and economical.
- the probiotic bacteria will remain in the gut for longer and enable the constant production of the antibody to enable more constant protection against the enteropathogenic microorganism.
- the amount of the micro-organism in food products of the invention is between 10 6 and 10 11 per serving or (for example if serving size is not known) between 10 6 and 10 11 per 100 g of product, more preferred these levels are from 10 8 to 10 9 per serving or per 100 g of product.
- the antibodies for use according to the present invention must be active in the gut/stomach, i.e. they must be functional and retain their normal activity including inactivating their target.
- the active antibodies according to the invention should bind to their target as normal, thus, the binding affinity of the antibody for the antigen should be as normal. Binding affinity is present when the dissociation constant is more than 10 5 .
- the food product or pharmaceutical preparation according to the invention will be able to selectively address a specific disease or symptom of a disease.
- the choice of antibody will determine the disease or symptom to be treated or reduced.
- the product when the product is a food product any antibody may be used. However, when the product is a pharmaceutical preparation heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof are preferred.
- VHH or VNAR type or domain antibodies dAbs
- the antibody or fragments thereof should have one or more of the following characteristics:
- the antibodies should be thermostable which enables their inclusion in a variety of food products.
- the food products may be prepared in a process requiring pasteurization and it is preferred that the activity of the antibodies is largely maintained despite heat treatment.
- the antibody or fragment thereof should be able to be expressed and secreted in the gut.
- assays are well known in the art which mimic GIT conditions and are used for instance to select suitable probiotics that can survive GIT conditions.
- a suitable assay for determining whether an antibody can survive the GIT conditions is described by Picot, A. and Lacroix, C. (International Dairy Journal 14 (2004) 505-515).
- the antibody produced is selected under specific conditions of low pH, preferably from 1.5 to 3.5, and in the presence of pepsin (a protease abundant in the stomach) to result in highly beneficial molecules that work well in the G/I tract and are suitable for use according to the present invention.
- pepsin a protease abundant in the stomach
- the present application may be applicable to the management of enteropathogenic micro-organisms in general.
- Enteropathogenic micro-organisms include viruses or enteropathogenic bacteria. Management is understood to mean therapy and/or prophylaxis.
- One further embodiment of the invention is a food product or pharmaceutical preparation containing the delivery system described above.
- Several food products may be prepared according to the invention, for example meal replacers, soups, noodles, ice-cream, sauces, dressing, spreads, snacks, cereals, beverages, bread, biscuits, other bakery products, sweets, bars, chocolate, chewing gum, diary products, dietetic products e.g. slimming products or meal replacers etc.
- food products of the invention may also be dietary supplements, although the application in food products of the above type is preferred.
- Table 1 indicates a number of products, which may be prepared according to the invention, and a typical serving size.
- An alternative means of administration of the delivery system comprising a micro-organism transformed with antibodies or functional fragments thereof comprises a dispensing implement for administering food which contains a coating of the delivery system on at least one of its surfaces.
- the term dispensing implement covers tube, straws, spoons or sticks or other implements which are used to deliver a liquid or semi-solid food product to a consumer.
- the dispensing implement may also be used to deliver a solid food product to a consumer.
- This dispensing tube or straw is especially suitable for use with certain beverages where high or low pH and/or temperature means that direct addition of the micro-organism to the beverage is not recommended
- the dispensing implement can also be used when the delivery system of the invention comprises encapsulated antibodies or even with antibodies per se.
- the dispensing implement contains on at least one surface a coating of the micro-organism, encapsulated antibodies or antibodies per se After the dispensing implement is coated with these particles, the implement is stored in an outer envelope which is impermeable to moisture and other contamination.
- the coating material which contains these particles is non-toxic to humans and to bacteria and can be an oil such as corn oil or a wax. This aspect is described in U.S. Pat. No. 6,283,294 B1. Once the dispensing implement containing these particles penetrates the beverage or semi-solid food product, the particles are integrated into the food product, giving a desirable dose of the antibodies with a serving of the product.
- the encapsulated particle, antibody per se or the micro-organism may be suspended in water which is then applied to the dispensing implement and evaporated.
- the dispensing implement will have a coating of the encapsulated particle, antibody per se or the micro-organism, which can then be released when the dispensing implement comes into contact with the liquid or semi-solid food product.
- a still further embodiment of the invention relates to a method for making a food product or pharmaceutical preparation comprising a delivery system for delivering antibodies to the GIT wherein the antibodies are active in the gut comprising adding the delivery system to the food product or pharmaceutical preparation during the manufacture of the food product.
- the micro-organism is alive in the product, thus, for example, if the product is heated during processing, the micro-organism has to be added after the heating step (post-dosing). However, if a product is fermented with the micro-organism, a heating step after the fermentation will not be acceptable. If the product is a liquid product, administration of the micro-organism could take place by use of a dispensing implement such as a drinking straw.
- a further embodiment of the invention relates to the use of the food product or pharmaceutical preparation comprising the delivery system according to the invention to deliver health benefits to the gut of a subject after administration.
- health benefits include the specific health benefit the antibody may provide.
- the micro-organism itself may also provide several health effects for example relating to gut well being such as IBS (Irritable Bowel Syndrome), reduction of lactose maldigestion, clinical symptoms of diarrhoea, immune modulation, anti-tumor activity, adjuvant effects and enhancement of mineral uptake.
- the food product or pharmaceutical preparation according to the present invention may be suitable for the management, including treatment or prophylaxis of infections caused by enteropathogenic bacteria or viruses.
- Other antibodies which may be incorporated into the invention will be able to provide a multitude of other health benefits.
- the present invention is based on the finding that heavy chain immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, of the invention may be used in the therapy or prophylaxis of infection by enteropathogenic micro-organisms. Furthermore, the immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, may be used in the therapy or prophylaxis of viral gastroenteritis or diarohoea caused by the enteropathogenic microorganism rotavirus.
- a further advantage of the present invention is that the use of food products or pharmaceutical preparations comprising probiotic micro-organisms expressing immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, enables the micro-organism, for example Lactobacillus , to provide the normal health benefits associated with this probiotic micro-organism, together with the prophylactic/therapeutic benefits in the management of the infection to be treated.
- This “dual effect” therapy provides greater health benefits to the subject than that known in the art.
- the heavy chain immunoglobulins or fragments thereof of the VHH type are derived from camelids, including llama and camels. Many llama derived heavy chain antibody fragments have been disclosed in the art. More preferred is the heavy chain immunoglobulin or fragment thereof which shows binding affinity with a dissociation constant of at least 10 exp 5 for rotavirus, especially rotavirus strains Wa, CK5, Wa1, RRV or CK5.
- llama heavy chain antibodies are effective in the management of rotavirus infection.
- the health benefit delivered will include an anti-diarhoeal effect.
- llama heavy chain antibodies can be used in the management of rotavirus infection, including the therapy or prophylaxis of rotavirus infection.
- llama VHH antibody fragments can reduce the viral load, normalize the pathology and mitigate diarrhoea during rotavirus infection.
- Rotavirus continues to be the single most common cause of infantile diarrhoea in the world and most children get infected during the first 5 years of life. In developing countries, rotavirus induced diarrhoea may cause 600,000 to 870,000 deaths each year and in developed countries, rotavirus disease accounts for immense economic loss.
- llama heavy chain antibodies have also unexpectedly been found to be suitable for administration in the gut.
- the llama heavy chain antibodies were found to be highly resistant to protease degradation in the stomach and to withstand the acidic environment of the stomach. This is despite the fact that the proteolytic system in the gut/stomach is more aggressive an environment than, for example encountered in the mouth.
- the in vivo production of antibody fragments locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach.
- the present invention is the first system which enables expression of antibodies in the GIT which are suitable for the management of rotavirus infection.
- the present invention is the first system which enables expression of antibodies in the GIT which are suitable for the management of rotavirus infection.
- the food product or pharmaceutical preparation can be administered in order to deliver a health benefit to the subject and/or to combat a specific disease or infection.
- the choice of the antibody will depend on the disease to be treated.
- the micro-organism is transformed with an expression vector comprising the gene for the llama heavy chain antibody or fragment thereof.
- an expression vector comprising the gene for the llama heavy chain antibody or fragment thereof.
- Either an integrating or a replicating vector may be used.
- the encapsulation method should survive passage to the stomach through the GIT and should be able to provide a sustained release of the antibody over a set period of time. This will ensure that the llama heavy chain antibody or fragment is delivered over time to the stomach. Llama heavy chain antibodies or heavy chains thereof are particularly suitable for this encapsulation method due to their ability to survive in the gut when released.
- the antibodies may be delivered to the GIT using a micro-organism transformed with llama heavy chain antibodies comprising the steps of i) transforming the micro-organism with the gene encoding llama heavy chain antibodies; and ii) administering the transformed micro-organism to the GIT of the human or animal in need of therapy.
- Fat levels may vary in a wide range e.g. full fat margarines with 60-90 wt % of fat, medium fat margarines with 30-60 wt % of fat, low fat products with 10-30 wt % of fat and very low or fat free margarines with 0 to 10 wt % of fat.
- the fat in the margarine or other spread may be any edible fat, often use are soybean oil, rapeseed oil, sunflower oil and palm oil. Fats may be used as such or in modified form e.g. hydrogenated, esterified, refined etc. Other suitable oils are well known in the art and may be selected as desired.
- the pH of a margarine or spread may advantageously be from 4.5 to 6.5.
- spreads other than margarines are cheese spreads, sweet spreads, yogurt spreads etc.
- Optional further ingredients of spreads may be emulsifiers, colourants, vitamins, preservatives, gums, thickeners etc.
- the balance of the product will normally be water.
- a typical size for an average serving of margarine or other spreads is 15 grams.
- Preferred VHH-producing Lactobacillus in the margarine or spread are 10 6 and 10 11 per serving most preferred 10 8 to 10 10 per serving.
- the Lactobacillus strain has to be added aseptically after the heating steps in the process.
- encapsulated VHH's may be added to these food products.
- frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
- the level of solids in the frozen confection is more than 3 wt %, more preferred from 10 to 70 wt %, for example 40 to 70 wt %.
- Ice-cream will typically comprise 2 to 20 wt % of fat, 0 to 20 wt % of sweeteners, 2 to 20 wt % of non-fat milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water.
- ice-cream will be aerated e.g. to an overrun of 20 to 400%, more general 40 to 200% and frozen to a temperature of from ⁇ 2 to ⁇ 200° C., more general ⁇ 10 to ⁇ 30° C. Ice-cream normally comprises calcium at a level of about 0.1 wt %.
- a typical size of an average serving of frozen confectionary material is 150 grams.
- Preferred Lactobacillus levels are from 10 6 and 10 11 per serving, more preferred these levels are from 10 7 to 10 10 per serving most preferred 10 8 to 10 9 per serving.
- the Lactobacillus strain has to be added aseptically after the heating steps in the process.
- encapsulated VHH's may be added to these food products.
- Lactobacillus can advantageously be used to beverages for example fruit juice, soft drinks etc.
- a very advantageous beverage in accordance to the invention is a tea based product or a meal replacers drink. These products will be described in more detail herein below. It will be apparent that similar levels and compositions apply to other beverages comprising vitamin producing Lactobacillus bacteria.
- tea based products refers to products containing tea or tea replacing herbal compositions e.g. tea-bags, leaf tea, herbal tea bags, herbal infusions, powdered tea, powdered herbal tea, ice-tea, ice herbal tea, carbonated ice tea, carbonated herbal infusion etc.
- herbal compositions e.g. tea-bags, leaf tea, herbal tea bags, herbal infusions, powdered tea, powdered herbal tea, ice-tea, ice herbal tea, carbonated ice tea, carbonated herbal infusion etc.
- tea based products of the invention may need a preparation step shortly before consuming, e.g. the making of tea brew from tea-bags, leaf tea, herbal tea bags or herbal infusions or the solubilisation of powdered tea or powdered herbal tea.
- a preparation step shortly before consuming, e.g. the making of tea brew from tea-bags, leaf tea, herbal tea bags or herbal infusions or the solubilisation of powdered tea or powdered herbal tea.
- the level of Lactobacillus in the product such that one serving of the final product to be consumed has the desired levels of Lactobacillus as described above.
- ice-tea For ice-tea, ice herbal tea, carbonated ice tea, carbonated herbal infusions the typical size of one serving will be 200 ml or 200 grams.
- Meal replacer drinks are typically based on a liquid base which may for example be thickened by means of gums or fibres and whereto a cocktail of minerals and vitamins are added.
- the drink can be flavoured to the desired taste e.g. fruit or choco flavour.
- a typical serving size may be 330 ml or 330 grams.
- Lactobacillus levels are 106 and 10 11 per serving, more preferred these levels are form 10 7 to 10 10 per serving most preferred 10 8 to 10 9 per serving.
- encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 ⁇ g per serving is added, more preferably between 50 and 500 ⁇ g are added per serving. Most preferably two or three servings are given each day.
- the aim is to ensure that one serving of 200 ml or 200 grams comprises the desired amounts as indicated above.
- the Lactobacillus present in the tea based product to be extracted will eventually be extracted into the final tea drink.
- the Lactobacillus may advantageously be incorporated into the tea component. However it will be appreciated that for some application it may be advantageous to separate the Lactobacillus from the tea, for example by incorporating it into a separate compartment of the tea bag or applying it onto the tea-bag paper.
- the oil phase of the emulsion generally is 0 to 80 wt % of the product.
- the level of fat is typically from 60 to 80%, for salad dressings the level of fat is generally 10-60 wt %, more preferred 15-40 wt %, low or no fat dressings may for example contain triglyceride levels of 0, 5, 10, 15% by weight.
- Dressings and mayonnaise are generally low pH products having a preferred pH of from 2-6.
- Dressings or mayonnaise optionally may contain other ingredients such as emulsifiers (for example egg-yolk), stabilisers, acidifiers, biopolymers, bulking agents, flavours, colouring agents etc.
- emulsifiers for example egg-yolk
- stabilisers for example acidifiers, biopolymers, bulking agents, flavours, colouring agents etc.
- the balance of the composition is water which could advantageously be present at a level of 0.1 to 99.9 wt %, more general 20-99 wt %, most preferred 50 to 98 wt %.
- a typical size for an average serving of dressings or mayonnaise is 30 grams.
- Preferred levels of Lactobacillus in such products would be 10 6 and 10 11 per serving, more preferred these levels are from 10 7 to 10 10 per serving most preferred 10 8 to 10 9 per serving.
- the Lactobacillus strain has to be added aseptically after the heating steps in the process.
- encapsulated VHH's may be added to these food products.
- the matrix may be a fat based (e.g. couverture or chocolate) or may be based on bakery products (bread, dough, cookies etc) or may be based on agglomerated particles (rice, grain, nuts, raisins, fruit particles).
- a typical size for a snack or meal replacement bar could be 20 to 200 g, generally from 40 to 100 g.
- Preferred levels of Lactobacillus in such products would be 10 6 and 10 11 per serving, more preferred these levels are from 10 7 to 10 10 per serving most preferred 10 8 to 10 10 per serving.
- the Lactobacillus strain has to be added aseptically after the heating steps in the process.
- encapsulated VHH's may be added to these food products.
- Preferably between 25 and 5000 ⁇ g per serving is added, more preferably between 50 and 500 ⁇ g are added per serving. Most preferably two or three servings are given each day.
- flavouring materials may be added to the product such as flavouring materials, vitamins, minerals etc.
- Lactobacillus per serving has been given as a preferred example. It will be understood that alternatively any suitable probiotic micro-organism may be present at this level.
- Lactobacillus can also be used in dry powders in sachets, to be dissolved instantly in water to give a refreshing lemonade.
- a powder may have a food-based carrier, such as maltodextrin or any other.
- additional ingredients may be colourants, vitamins, minerals, preservatives, gums, thickeners etc.
- a typical size for an average serving or margarine or other spreads is 30-50 grams.
- Preferred VHH-producing Lactobacillus in the lemonade powder are 10 6 and 10 11 per serving most preferred 10 8 to 10 10 per serving.
- the Lactobacillus strain has to be sprayed on the carrier in such a way that it is kept alive, according to methods known by those skilled in the art.
- encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 ⁇ g per serving is added, more preferably between 50 and 500 ⁇ g are added per serving.
- the transformed micro-organism can be added as viable cultured (wet) biomass or as a dried preparation, still containing the viable micro-organisms as known in the art.
- Rhesus rotavirus strain RRV (serotype G3) was purified, amplified and concentrated as described previously (Svensson L., Finlay B. B., Bass D., Vonbonsdorff C. H., Greenberg H. B. “Symmetrical infection on polarised human intestinal epithelial (CaCo-2) cells”. J Virol. (1991) 65, 4190-4197.
- a llama was immunized subcutaneously and intramuscularly at day 0, 42, 63, 97 and 153 with 5 ⁇ 10 12 pfu of rotavirus strain RRV.
- RNA between 250 and 400 ug was isolated by acid guanidium thiocyanate extraction Chomczynski, P. and Sacchi, N. “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction”. Anal. Biochem. (1987) 162:156-159. Subsequently, first strand cDNA was synthesized using the Amersham first strand cDNA kit (RPN1266). In a 20 ⁇ l reaction mix 0.4-1 ⁇ g mRNA was used. The 6-mer random primer was used to prime the first DNA strand. After cDNA synthesis, the reaction mix was directly used for amplification by PCR. VHH genes were amplified with primers
- Lam-16 (GAGGTBCARCTGCAGGASAGYGG); Lam-17: (GAGGTBCARCTGCAGGASTCYGG); Lam-07 (priming to the short hinge region); and Lam-08 (long hinge specific)
- the amplified products were digested with PstI and NotI (New England Biolabs, US) and cloned in phagemid vector pUR5071, which is based on pHEN1 (Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P. and Winter, G. “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains”. Nucleic Acids Res.
- Soluble VHH was produced by individual E. coli TG1 clones as described by Marks J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. and Winter, G. “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991) 222: 581-597. Culture supernatants were tested in ELISA.
- Microlon F (Greiner Bio-One GmbH, Germany) plates were coated with 50 ⁇ l/well of a 1:1000 dilution of either anti-rotavirus rabbit polyclonal sera or anti-rotavirus guinea pig polyclonal sera in carbonate buffer (16% (v/v) 0.2 M NaHCO3+9% (v/v) 0.2 M Na2CO3) and subsequently incubated with rotavirus strain RRV or CK5 (approx. 109 pfu/ml).
- VHH's were detected with a mixture of the mouse anti-myc monoclonal antibody 9E10 (500 ng/ml, in-house production) and anti-mouse HRP conjugate (250 ng/ml, Dako, Denmark). Alternatively, detection was performed with anti-6 ⁇ His-HRP antibody conjugate (1000 ng/ml, Roche Molecular, US). Fingerprint analysis (Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. and Winter, G. “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991) 222: 581-597) with the restriction enzyme HinFI (New England Biolabs, US) was performed on all clones. Sequencing was performed at Baseclear B.V. (Leiden, The Netherlands).
- a set of rotavirus-specific antibody fragments was selected. DNA sequences encoding these antibody fragments were isolated from pUR5071 (PstI/BstEII, New England Biolabs, US)) and cloned into pUR4547 which is identical to the previously described pUR4548 (Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae ”. J. Biotechnol. (2000) 78, 11-21) but does not encode any C-terminal tag-sequences.
- This episomal yeast expression vector contains the GAL7 promoter, the SUC2 signal sequence for high level expression and secretion into the growth medium, respectively.
- the S. cerevisiae strain VWK18gal1 was transformed and induced for antibody fragment production as described previously (Van der Vaart, J. M., “Expression of VHH antibody fragments in Saccharomyces cerevisiae ”. In Methods in Molecular Biology (2001) Vol. 178, p 359-366, Edited by P. M. O'Brien and R. Aiken, Humana Press Inc., Totowa, N.J.). Antibody fragments were purified and concentrated by filtration over microcon filters with a 10 kDa cut-off (Amicon, US).
- Bovine Rotavirus Compton CK5 was obtained from the Moredun Institute, Midlothian, Scotland and the BS-C1 cells were purchased from the European Animal Cell Culture Collection.
- the BS-C1 cells were cultured in Earles Modified Essential Medium supplemented with 10% Heat inactivated foetal calf serum, 1% MEM Amino Acids solution (100 ⁇ ), 20 mmol l-1 L-Glutamine, 100 I.U. ml-1 penicillin, 100 ⁇ g ml-1 streptomycin and 2.5 ⁇ g ml-1 amphotericin B (all from Sigma, US).
- CK5 Rotavirus stock was diluted in Serum Free Medium (SFM) EMEM supplemented with 1% MEM Amino Acids solution (100 ⁇ ), 20 mmol l-1 L-Glutamine and 0.54 ml crystalline trypsin and then 5 ml of diluted seed was added to confluent monolayers of BS-C1 cells in 162 cm 2 tissue culture flasks (Costar, UK). The virus was adsorbed onto the cells for one hour at 37° C. then the medium was topped up to 75 ml. The bottles were incubated at 37° C. until complete cytopathic effect was observed.
- SFM Serum Free Medium
- Cultures were frozen ( ⁇ 70° C.) and thawed twice, then pooled and centrifuged at 1450 g for 15 minutes at 4° C. to remove cell debris. The supernatant was decanted and stored in aliquots at ⁇ 70° C.
- Monolayers of BS-C1 cells were cultured in 12-well tissue culture plates at 37° C. in an atmosphere of 95% air and 5% carbon dioxide. The medium was removed and replaced with SFM for at least 2 hours prior to use.
- the CK5 virus was diluted to give approximately 50 pfu/ml in SFM.
- the selected anti-rotavirus fragments were diluted in SFM and then equal volumes of virus and fragment dilution were mixed (200 ⁇ l total volume) and incubated for one hour at 37° C.
- the virus-fragment mixtures were then plated onto the monolayers of cells (three replicate wells each). The plates were incubated for one hour at 37° C. in an atmosphere of 95% air and 5% carbon dioxide. Subsequently, the virus was removed and an overlay consisting of 0.75% Sea Plaque Agarose (FMC) in EMEM containing 100 I.U. ml-1 penicillin, 100 ⁇ g ml-1 streptomycin, 2.5 ⁇ ml-1 amphotericin B and 0.1 ⁇ g/ml crystalline trypsin was added. Plates were then incubated at 37° C. in an atmosphere of 95% air and 5% carbon dioxide for 4 days. After fixing and staining with 1% crystal violet in 10% formaldehyde, the agarose was removed, the wells washed with water and the plaques counted.
- FMC Sea Plaque Agarose
- FIG. 1 shows virus neutralisation of rotavirus CK5 determined by an in vitro plaque assay. The average neutralisation-rate from the four obtained measurements is indicated at each data-point. If there is a spread of over 10% at a data point, the two most extreme measurements are indicated (dashed bar). The tested antibody fragments were divided over 2 graphs, A and B. A's negative controls either the virus was omitted (no virus) or a non-rotavirus specific VHH was added. The non-specific VHH fragment is specific for the human pregnancy hormone hCG.
- VHH fragments were identified that can inhibit rotavirus infection in an in vitro system.
- VHH fragments selected via the approach described in example 2 were used in in vivo experiments to study the efficacy of these antibody fragment in the prevention or treatment of rotavirus induced diarrhoea in mice.
- This model system has been frequently used for study of rotavirus infection (Ebina, T, Ohta, M, Kanamaru, Y, Yamamotoosumi, Y, Baba, K. “Passive immunisations of suckling mice and infants with bovine colostrum containing antibodies to human rotavirus”. J Med Virol. (1992) 38: 117-123).
- mice 14 days pregnant, rotavirus negative BALB/c mice were obtained from Mölleg ⁇ rd, Denmark. The mice were housed individually in the animal facility at Huddinge Hospital. Approval was obtained from the local ethical committee of Karolinska Institute at Huddinge Hospital, Sweden. Normal pellet diet and water was provided ad libitum.
- VHH fragments were premixed with titrated amounts (2 ⁇ 107 ffu) of RRV before it was used for infection on day 1.
- mice pups Four-day old mice pups were treated daily with VHH fragments, including day 0 (day before infection) up to and including day 4 ( FIG. 2 ) and diarrhoea was assessed. A marked reduction in occurrence of diarrhoea was observed for antibody fragment 2B10, shown in FIG. 2 . The number of pups with diarrhoea is significantly lower at day 2 in the group receiving fragment 2B10 compared to the untreated group. Moreover, at days 3, 4 and 5 none of the pups in 2B10 treated group displayed signs of diarrhoea compared to the majority of the pups in the other RRV treated groups ( FIG. 2 ).
- the mean number of diarrhoea days per mouse pup were calculated for each treatment group as the number of diarrhoea days per pup divided by the total number of pups per treatment group. For the fragment 2B10 treated groups this was found to be significantly reduced to 0.33 ⁇ 0.21 days compared to 2.87 ⁇ 0.29 days for the untreated group.
- Variable region encoding sequences of both the heavy (VH) and light (VK) chains were amplified using a 5′ RACE kit (5′ RACE System for Rapid Amplification of cDNA Ends (Version 2.0, InvitrogenTM life technologies, Carlsbad, Calif.).
- the primers for the 5′ RACE of VH were amplified using a 5′ RACE kit (5′ RACE System for Rapid Amplification of cDNA Ends (Version 2.0, InvitrogenTM life technologies, Carlsbad, Calif.). The primers for the 5′ RACE of VH were
- ACRACE1 5′-CAGACTCAGGATGGGTAAC-3′
- ACRACE2 5′-CACTTGAATGATGCGCCACTGTT-3′
- ACRACE3 5′-GAGGGCTCCCAGGTGAAGAC-3′
- the primers mkRACE1 (5′-TCATGCTGTAGGTGCTGTCT-3′), mkRACE2 (5′-TCGTTCACTGCCATCAATCT-3′) and mkRACE3 (5′-TGGATGGTGGGAAGATGGAT-3′) were utilized to amplify the variable region of the light chain.
- the resulting A-tailed PCR product was cloned into a pGEM ⁇ -T easy vector with 3′-T overhangs and sequenced.
- VH and VK sequences were fused together with a linker encoding gene (with the amino acid sequence (G4S)3). Both chains were re-amplified from the cloned 5′ RACE products using the primers ClaI-VHs (5′-TTTTATCGATGTGCAGTTGGTGGAGTCTGG-3′) and Linker-VHas (5′-CGATCCGCCACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCACCTGAGGA GACGGTGACCGTGG-3′); Linker-VKs (5′-GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACAT TGTGATGACCCAGTC-3′) and EcoRI-Vkas (5′-TTTTGAATTCTTTTATTTCCA GCCTGGTCC-3′).
- VH and VK PCR products were mixed together and used as a template for a fusion PCR using the primers ClaI-VHs and EcoRI-VKas.
- the fused PCR products were cloned into a pGEM ⁇ -T easy vector after addition of overhang A using Taq DNA polymerase.
- the fused scFv-2A10 encoding sequence was finally cut out from the plasmids using EcoRI plus ClaI and subcloned into pBluescript II SK (+) (Stratagene, La Jolla, Calif.) containing an E-tag (pBS-E-tag).
- the VHH1 was amplified from pUR655 using a sense primer containing ClaI restriction site and an anti-sense primer containing EcoRI restriction site and then inserted into the pBS-E-tag vector.
- the scFv-2A10-E-tag and the VHH1-E-tag were excised from the pBS-E-tag vector using ClaI and XhoI restriction sites, and fused to an anchor sequence, the last 244 amino acids of the proteinase P protein of L. casei (Kruger et al, Nature Biotechnol (2002) 20:702-706), into the Lactobacillus expression vector pLP502 ( FIGS. 3A and 3C ).
- a stop codon was inserted by PCR amplification after the E-tag and the products were inserted into pLP502 between the ClaI and XhoI restriction sites ( FIGS. 3B and 3D ).
- the pLP502 vector contains the constitutive promoter of the lactate dehydrogenase gene (Pldh).
- Pldh lactate dehydrogenase gene
- cDNA was used for the generation of a standard curve for 16SrRNA and the antibody insert using the primers p0 (5′GAGAGTTTGATCCTGGCTCAG 3′) and p6 (5′CTACGGCTACCTTGTTACGA 3′) for the 16SrRNA and primers prtpsp (5′TCTTGCCAGTCGGCGAAAT 3′) and XhoI-VHH (5′CCGCTCGAGTGCGGCACGCGGTTCC 3′) for the insert.
- L. paracasei containing the constructs were cultured to an OD600 of 0.8. After centrifugation, the pH of the supernatants was adjusted to 7 and filtered through a 0.45 ⁇ m filter. The secreted antibody fragments were subsequently purified according to the instructions provided in the RPAS Purification Module (Amersham-Bioscience, Little Chalfont, Buckinghamshire, UK). Dialysis overnight at 8 C was performed with a Spectra/Por ⁇ membrane MWCO 6-8000 (Spectrum Medical Industries, Inc., Los Angeles, Calif.) against 1 ⁇ PBS. The purified antibody fragments were run on a 15% SDS-poly acrylamide gel to verify the purity of the sample and the concentration of total protein was determined by the BioRad protein assay (BioRad Laboratories, Hercules, Calif.).
- L. paracasei containing the constructs 2A10-anchor, VHH1-anchor, 2A10-secreted, VHH1-secreted, irrelevant-secreted and irrelevant-anchor were cultured in MRS broth containing 3 ⁇ g/ml erythromycin to an OD600 of 0.8.
- the bacteria were lysed in 10 mM Tris-HCl pH 8.0 containing 10 mg/ml lysozyme at 37 C for one hour and then disrupted by sonication (6 ⁇ 30 s on/off cycles) with 60% duty cycle (Digital Sonifier, model 250, Branson Ultrasonics corporation, Danbury, Conn.). Debris was removed by centrifugation. The supernatants were concentrated 50 ⁇ using ultrafiltration (Amicon, Beverly, Mass.). BioRad protein assay was used to determine the protein concentration as described above.
- ELISA 96 well plates were coated with rabbit anti-human rotavirus sera (1/1000). 1:100 dilution of Rhesus rotavirus stock (RRV) was used for secondary coating. After blocking, the plates were incubated with the protein extracts or concentrated supernatants.
- RRV Rhesus rotavirus stock
- Mouse anti-E-tag antibodies (Amersham Pharmacia Biotech, Bucks, UK) or rabbit anti-llama antibodies, horse radish (HRP) conjugated goat anti-mouse antibodies or swine anti-rabbit antibodies (DAKO A/S, Glostrup, Denmark) and 3,3′,5,5′-tetramethylbenzidine substrate (TMB) were added and the absorbance was measured at 630 nm using a Vmax Microplate Reader (Molecular Devices, Sunnyvale, Calif.). All antibodies were diluted 1/1000. Purified VHH1-E-tag and monoclonal 2A10 antibodies were used as standard to determine the concentration of antibody fragments produced by the different lactobacilli transformants.
- Results are shown in FIG. 4 a.
- SEM Scanning Electron Microscope
- TEM Transmission Electron Microscope
- Results are shown in FIG. 4 b and FIG. 11 .
- Rhesus rotavirus was cultured in MA104 cells as previously described. Plaque-purified RRV was used throughout the study. A single virus stock was produced for the entire study by infecting MA104 cells with RRV at a multiplicity of infection (MOI) of 0.1 in serum-free M199 medium (Gibco Laboratories, Grand Island, N.Y.) containing 0.5 ⁇ g of trypsin (Sigma Chemical Co., St. Louis, Mo.) per ml. When the cytopathogenic effect reached approximately 75% of the monolayer, cells were freeze-thawed twice and cell lysates were cleared by low-speed centrifugation. The virus suspension was divided into aliquots and stored at ⁇ 80° C. until use. Determination of virus titers was performed by an immunoperoxidase focus reduction test. A single virus stock was produced for the entire study.
- MOI multiplicity of infection
- Antibody expressing lactobacilli were further tested for inhibitory effect on rotavirus by a microneutralization assay as described previously (Giammarioli et al 1996 as above).
- the bacteria were serially diluted in MEM media and incubated for 1 h at 37° C. with 200 ffu of trypsin-activated RRV (100 ⁇ l). At the end of incubation, bacteria were removed by centrifugation and the supernatant was used for inoculating MA104 cell monolayers grown in 96-well plates.
- Concentrated culture supernatants from lactobacilli secreting antibody fragments were used for incubation with RRV and inoculation of MA104 cell monolayers.
- the inoculated plates were incubated at 37° C. for 1 hrs, washed with MEM medium, supplied with fresh MEM medium supplemented with antibiotics (gentamycin and penicillin/streptomycin) and incubated at 37° C. in a CO2 atmosphere for 18 h.
- Monolayers were fixed and stained with immunoperoxidase as described (Svensson et al 1991 as above). A reduction in the number of RRV-infected cells greater than 60% with respect to the number in control wells was considered to indicate neutralization.
- Purified VHH1 fragments produced by lactobacilli were used as a positive control.
- Results are shown in FIG. 5 .
- mice All animal experiments were approved by the local ethical committee of the Karolinska Institutet at Huddinge Hospital, Sweden. Pregnant BALB/c female mice were purchased from M ⁇ llegard, Denmark. Four-day-old pups were used for the study. Pups were fed 10 ⁇ l of different treatments once a day, starting on day ⁇ 1 until day 3. Lactobacilli were administered once, one day before rotavirus challenge. Infections were made orally on day 0 using 2 ⁇ 10 7 pfu RRV in 10 ⁇ l volume.
- Results are shown in FIG. 6 .
- Sections of the small intestine were taken on day 4 and perfused with 4% neutral buffered formalin and Hematoxylin and Eosin staining was performed after sectioning according to standard protocols. Individual slides were evaluated blindly for typical signs of rotavirus infection.
- Total cellular RNA was isolated from small intestinal tissue and was used for Real Time analysis after digestion of residual genomic DNA using RNase free DNase®.
- EZ RT-PCR® core reagent kit PE Applied Biosystems, Foster City, Calif., USA
- a standard curve was generated using a pet28a (+) vector with the RRV vp7 gene cloned between the NcoI and XhoI restriction sites.
- Rotavirus vp7 mRNA or viral genomic RNA was amplified at 58° C. (ABI 7000 cycler, Applied Biosystems) in the presence of 600 nM primers, 300 nM probe, 5 mM Mn to generate a 121 bp long amplicon.
- the sense primer (VP7f: 5′-CCAAGGGAAAAT GTAGCAGTAATTC-3′) (nucleotide (nt) 791-815), the antisense primer (VP7r: 5′-TGCCACCATTCTTT CCAATTAA-3′), (nt 891-912), and the probe (5′-6FAM-TAACGGCTGATCCAACCACAGCACC-TAMRA-3′ (nt 843-867) were designed based on the vp7 gene sequence of rhesus rotavirus (accession number AF295303). The lowest level of detection of the PCR is 10 viral RNA copies.
- RNA samples from each animal was normalized for the internal housekeeping gene control GAPDH (Overbergh et al, (1999) Cytokine 11: 305-312). Detection of no virus or less than 10 virus genomes was defined as clearance from infection.
- Results are shown in FIG. 7 .
- Feacal samples of three animals from the groups receiving the lactobacilli expressing the VHH1 anchored fragments, non-transformed lactobacilli or a non treated group were collected at the day of termination.
- the samples were smeared on a Super frost coated glass slide and fixed by methanol:acetone (1:1) for 10 minutes on ice.
- a mouse anti-E-tag antibody (1/200) and thereafter a cy2 labelled donkey anti-mouse antibody (1/200) was added to the slides and incubated for 1 hour under humid conditions.
- the surface expressed VHH1 fragments were detected by fluorescence microscope.
- the diarrhoeal illness in pups was assessed on the basis of consistency of feces. Watery diarrhoea was given a score 2 and loose stool was given a score 1, no stool or normal stool was given a score 0. The percentage of diarrhoea score was calculated each day. Total daywise score in a treatment group was compared to untreated group by Fisher's exact test. Severity was defined as the sum of diarrhoea score for each pup during the course of the study and duration was defined as the sum of days with diarrhoea. Both severity and duration were analysed by Kruskal Wallis and Dunn tests.
- FIG. 4 a shows the surface expression of the 2A10-scFv and VHH1 by lactobacilli was shown by flow cytometry using an anti-E-tag antibody A lower level of detection of the E-tag was observed on lactobacilli producing the 2A10 anchored fragments compared to the VHH1 anchored and irrelevant scFv and VHH control fragments expressing bacteria (data not shown).
- the binding activity of the antibody fragments was analyzed by ELISA and electron microscopy.
- ELISA homogenates of 2A10-anchor- and VHH1-anchor-transformed lactobacilli and supernatant from the 2A10-secreted- and VHH1-secreted-transformed lactobacilli were tested using the E-tag for detection.
- a higher level of binding was observed for the llama VHH1 fragments, both anchored and secreted (purified and from the supernatant).
- the amount of secreted 2A10 was too low to be detected by ELISA.
- the non-transformed L. paracasei , irrelevant antibody fragments from transformed lactobacilli expressing anchored or secreted scFv and anchored or secreted VHH did not bind to rotavirus (data not shown).
- the amount of antibody fragments produced by the VHH1-anchor transformants was calculated to be approximately 10 4 VHH1 fragments/bacteria, and 600 2A10 fragments/bacteria (intracellular and on the surface).
- the VHH1-secreted transformants produced approximately 1 ⁇ g/ml of VHH1 fragments in the supernatant.
- FIGS. 4 b and 11 a show lactobacilli expressing VHH1 antibody fragments on their surface, which were incubated with rotavirus and then analyzed by SEM. The results showed binding of the virus on the bacterial surface ( FIGS. 4 ba and 11 b ), but not to a non-transformed L. paracasei strain ( FIG. 11 b ).
- TEM negative staining
- binding to the virus by llama antibody fragments from the supernatant of lactobacilli transformed with the VHH1-secreted vector could be demonstrated, whereas the non-transformed L. paracasei strain control supernatant did not bind rotavirus (data not shown).
- FIG. 5 The effect of Lactobacillus produced antibody fragments in a rotavirus neutralization assay was analysed in FIG. 5 .
- the solid line of this figure represents neutralization level achieved by lactobacilli produced E-tag purified VHH1 antibody (20 ⁇ g/ml). Dotted line indicates the neutralization level of 2A10 monoclonal hybridoma supernatant (147 ng/ml). Neutralization achieved by different concentrations of VHH1 anchored lactobacilli ( ⁇ ), 2A10 anchored lactobacilli ( ) and non-transformed lactobacilli ( ⁇ ).
- FIG. 5 The solid line of this figure represents neutralization level achieved by lactobacilli produced E-tag purified VHH1 antibody (20 ⁇ g/ml). Dotted line indicates the neutralization level of 2A10 monoclonal hybridoma supernatant (147 ng/ml). Neutralization achieved by different concentrations of VHH1 anchored lactobacilli ( ⁇ ), 2A10 anchored lac
- FIG. 6 shows the prevalence of diarrhoea in mice treated with lactobacilli expressing VHH1-anchored fragments.
- FIG. 7 shows that in the untreated group, histology of the duodenum and jejunum sections reveals typical signs of rotavirus infection; swelling of villus tips, vacuolization, constriction of villus bases and unpolarized nuclei within cells (a).
- FIG. 8 shows that the mean viral load in VHH1 anchored treatment group is at least 200 fold lower than untreated group. A probiotic effect of irrelevant lactobacilli controls was also seen (10 fold reduction in viral load). Clearance from virus was defined as no vp7 detection or detection of less than 10 vp7 RNA molecules. 27% animals were cleared of rotavirus in VHH1 anchored treatment group as compared to 9% in untreated group.
- Pups were fed lactobacilli expressing the anchored VHH1 against rotavirus once (on day 0) and half of them were subsequently infected with RRV on day 1. Two pups in each group were sacrificed every second day and checked for the presence of Lactobacillus transformants by culturing of the intestinal content. The bacteria could be detected in the duodenum and the ileum 48 h post treatment with no difference between the rotavirus infected and uninfected groups, whereas at 96 h post treatment, no transformants could be detected (data not shown).
- the therapeutic effect of the transformed lactobacilli was tested in a mouse pup model of rotavirus-induced diarrhea.
- Pups were orally fed lactobacilli expressing the 2A10-scFv or the VHH1 in secreted or anchored forms during five days (day ⁇ 1 to 3) and infected with RRV on day 0.
- Control groups included non-transformed L. paracasei and bacteria expressing an irrelevant anchored VHH antibody fragment.
- 108 CFU as the optimal dose for diarrhea intervention ( FIG. 9 ).
- the surface VHH1 expressing bacteria shortened the disease duration (normal duration 1.2 days) by approximately 0.9 days (P ⁇ 0.01) and by 0.7 days compared to mice treated with non-transformed L. paracasei (P ⁇ 0.05).
- the severity of the diarrhea was also reduced from 3.7 to 1.7 in mice treated with surface VHH1 expressing lactobacilli as compared to the disease severity in untreated pups (P ⁇ 0.001) and by a factor of 1.2 in comparison to pups treated with non-transformed L. paracasei (P ⁇ 0.01).
- a minor probiotic effect by the non-transformed lactobacilli was also observed (Table 2).
- the diarrhea prevalence was significantly lowered both on days 2 and 3 in mice treated with the Lactobacillus expressing surface VHH1 in comparison to untreated mice (P ⁇ 0.0001, for both days) or mice treated with non-transformed L. paracasei (P ⁇ 0.02, for day 2) ( FIG. 6 a ).
- Histological examination of proximal small intestine sections on day 4 revealed a marked reduction of pathological changes in rotavirus infected animals treated with surface VHH1 expressing lactobacilli and in some mice, the histology was completely normalized.
- the histology in the group receiving no lactobacilli revealed typical signs of rotavirus infection with swelling of villus tips, constriction of villus bases, vacuolization and irregularly placed cell nuclei ( FIG. 7 a,b,c,d ).
- To assess whether there was a reduction in viral replication in the enterocytes a real time PCR for expression of the rotavirus vp7 gene was developed.
- the mean viral load in animals receiving lactobacilli expressing surface bound VHH1 antibody fragments was at least 250 fold lower than in untreated mice. Lactobacilli expressing an irrelevant VHH fragment also reduced the viral vp7 load (up to 10 fold). The clearance rate was 27% in the group given lactobacilli expressing surface anchored VHH1 as compared to 9% in the untreated group ( FIG. 8 ).
- a solution of 2% sodium alginate was added dropwise to a solution of 0.1 M calcium chloride, containing 1% of the VHH, resulting in the formation of calcium alginate beads (with a size of about 2 mm).
- the dispersion was allowed to stand for 30 min for the calcium alginate beads to settle at the bottom of the beaker.
- the beads were then collected with a sieve and washed once with water
- An ice cream composition was prepared having the following formulation:
- All the ice cream ingredients were mixed together using a high shear mixer for approximately 3 minutes.
- the water being added at a temperature of 80° C.
- the temperature of the water ice mix was approximately 55-65° C. after mixing.
- the mix was then homogenized (2000 psi) and passed through to a plate heat exchanger for pasteurization at 81° C. for 25 seconds. The mix was then cooled to approximately 4° C. in the plate heat exchanger prior to use.
- an anti-rotavirus VHH producing Lactobacillus strain can be added instead of the encapsulated VHH solution, preferably in a concentration of 109 per serving or higher.
- the ice cream pre-mix was then frozen using a Technohoy MF 75 scraped surface heat exchanger, no overrun was introduced into the ice cream.
- the ice cream was extruded at a temperature of from 4.4° C. to ⁇ 5.4° C.
- the product was then hardened in a blast freezer at ⁇ 35° C., then stored at ⁇ 25° C.
- a water ice solution having the following composition was prepared as follows;
- the mix was then homogenized (2000 psi) and passed through to a plate heat exchanger for pasteurization at 81° C. for 25 seconds. The mix was then cooled to approximately 4° C. in the plate heat exchanger prior to use.
- a anti-rotavirus VHH producing Lactobacillus strain can be added preferably in a concentration of 109 per serving or higher.
- the water ice solution was frozen in a Technohoy MF 75 scraped surface heat exchanger with an overrun (volume fraction of air) of 30%.
- the water ice was extruded at a temperature of from ⁇ 3.8° C. to ⁇ 4.5° C.
- the product was then hardened in a blast freezer at ⁇ 35° C., and stored at ⁇ 25° C.
- compositions for Spreads Containing Encapsulated Anti-Rotavirus VHH or a Lactobacillus Producing this VHH
- a anti-rotavirus VHH producing Lactobacillus strain can be added aseptically, preferably in a concentration of 109 per serving or higher.
- the bacterial strain is cultured in a suitable food raw material (e.g. milk) to achieve a high density of the culture and sufficient production of the VHH.
- a suitable food raw material e.g. milk
- the cultured raw material is mixed with the typical ingredients of dressings (like oil, vinegar, egg yolk, salt) at a level that supports efficacy of the VHH and subjected to standard processing of mayonnaise, like mixing and homogenisation.
- the typical ingredients of dressings like oil, vinegar, egg yolk, salt are first mixed and subjected to a heat treatment and homogenisation followed by the addition of the cultured raw material.
- encapsulated anti-rotavirus VHH obtained according to example 5 can be added.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
- The present invention relates to heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof suitable for use in the management of infections by enteropathogenic micro-organisms. The present invention also relates to a delivery system comprising these heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and hosts comprising expression vectors encoding for these heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof. The invention further relates to food products or pharmaceutical preparations comprising a delivery system for delivering antibodies to the gastro-intestinal tract (GIT) wherein the antibodies are active in the gut.
- Immunoglobulins (also called antibodies) are glycoproteins, which specifically recognise foreign molecules. These recognised foreign molecules are called antigens. When antigens invade humans or animals, an immunological response is triggered which involves the production of antibodies by B-lymphocytes. By this immunological response, microorganisms, larger parasites, viruses and bacterial toxins can be rendered harmless. The unique ability of antibodies to specifically recognise and bind with high affinity to virtually any type of antigen, makes them useful molecules in medical and scientific research.
- In vertebrates five immunoglobulin classes are described, including IgG, IgM, IgA, IgD and IgE, all of which differ in their function in the immune system. IgGs are the most abundant immunoglobulins in the blood. They have a basic structure of two identical heavy (H) chain polypeptides and two identical light (L) chain polypeptides. The H and L chains are kept together by disulfide bridges and non-covalent bonds. The chains themselves can be divided in variable and constant domains. The variable domains of the heavy and light chain (VH and VL) which are extremely variable in amino acid sequences are located at the N-terminal part of the antibody molecule. VH and VL together form the unique antigen-recognition site. The amino acid sequences of the remaining C-terminal domains are much less variable and are called CH1, CH2, CH3 and CL.
- The non-antigen binding part of an antibody molecule is called the constant domain Fc and mediates several immunological functions, such as binding to receptors on target cells and complement fixation. The unique antigen-binding site of an antibody consists of the heavy and light chain variable domains (VH and VL). Each domain contains four framework regions (FR) and three regions called CDRs (complementarity determining regions) or hypervariable regions. The CDRs strongly vary in sequence and determine the specificity of the antibody. VL and VH domains together form a binding site, which binds a specific antigen.
- Several functional antigen-binding antibody fragments could be engineered by proteolysis of antibodies, using for example papain digestion, pepsin digestions or other enzymatic approaches. Such a technique can be used to yield Fab, Fv or single domain fragments. Fab fragments are the antigen-binding domains of an antibody molecule. Fab fragments can be prepared by papain digestions of whole antibodies. Fv fragments are the minimal fragment (˜30 kDa) that still contains the whole antigen-binding site of a whole IgG antibody. Fv fragments are composed of both the variable heavy chain (VH) and variable light chain (VL) domains. This heterodimer, called Fv fragment (for fragment variable) is still capable of binding the antigen.
- Heavy chain antibodies constitute about one fourth of the IgG antibodies produced by the camelids, e.g. camels and llamas (Hamers-Casterman C., et al. (1993)). These antibodies are formed by two heavy chains but are devoid of light chains. As a consequence, the variable antigen binding part is referred to as the VHH domain and it represents the smallest naturally occurring, intact, antigen-binding site, being only around 120 amino acids in length (Desmyter, A., et al. (2001)). Heavy chain antibodies with a high specificity and affinity can be generated against a variety of antigens through immunization (van der Linden, R. H., et al. (1999)) and the VHH portion can be readily cloned and expressed in yeast (Frenken, L. G. J., et al. (2000)). Their levels of expression, solubility and stability are significantly higher than those of classical F(ab) or Fv fragments (Ghahroudi, M. A. et al. (1997)). Sharks have also been shown to have a single VH-like domain in their antibodies termed VNAR. (Nuttall et al. (2003)); (Dooley et al. (2003)); (Nuttall et al. (2004)).
- Holt et al. (2003) reviews antigen-binding fragments called “domain antibodies” or dAbs which comprise only the VH or VL domain of an antibody and are consequently smaller than, for example, Fab and scFv. DAbs are the smallest known antigen-binding fragments of antibodies, ranging from 11 kDa to 15 kDa. They are highly expressed in microbial cell culture. Each dAb contains three of the six naturally occurring complementarity determining regions (CDRs) from an antibody.
- The production of antibodies for use in conventional immunotherapy has been possible since the development of monoclonal antibody technology. This has led to the use of antibodies in many areas including research, medicine and recently in consumer applications.
- Unfortunately, there are many problems associated with conventional immunotherapy. Such applications rely on the large scale production of antibodies and involve the use of the antibody or antibody fragment per se, that is the harvested protein from, for example, an antibody expression system. Thus, the associated production costs, including the requirement for purification of the antibodies before administration, are expensive and make their wide scale application as immunotherapeutics prohibitive. Furthermore, in order to treat a large part of the population, large amounts of conventional immunotherapy products would be required. If, for example, the therapy was based on colostrum and/or immunised chicken eggs, it would be difficult to provide the required amounts of the immunotherapy products in a large volume.
- Furthermore, in a recent article, “In situ delivery of passive immunity by lactobacilli producing single-chain antibodies” Nature Biotechnol. (2002) 20, 702-706, Kruger et al reported on the production of scFv antibody fragments against Streptococcus mutans by the Gram positive food grade bacteria Lactobacillus zeae. This treatment involved in situ delivery of passive immunity at oral mucosal sites only wherein the single chain antibody fragments were shown to deliver protection against dental caries in rats.
- Lactobacilli have been investigated with regards to their anti-diarrhoeal properties since the 1960's (Beck, C., et al. Beneficial effects of administration of Lactobacillus acidophilus in diarrhoeal and other intestinal disorders. Am. J. Gastroenterol (1961) 35, 522-30). A limited number of recent controlled trials have shown that certain strains of lactobacilli may have therapeutic as well as prophylactic properties in acute viral gastroenteritis (Mastretta, E., et al. Effect of Lactobacillus CG and breast-feeding in the prevention of rotavirus nosocomial infection. J. Pediatr. Gastroenterol. Nutr. (2002) 35, 527-531). Selected strains of Lactobacillus casei and Lactobacillus plantarum have also been shown to exert strong adjuvant effects on the mucosal and the systemic immune response.
- Lactobacilli are well-known bacteria applied in the production of food products. For example yogurt is normally made by fermenting milk with among others a Lactobacillus strain. The fermented acidified product, still containing the viable Lactobacillus, is then cooled and consumed at the desired moment.
- Another application of Lactobacillus in food products is in the production of meat products for example sausages. Here the Lactobacillus is added to the meat mass prior to applying the casing, followed by a period of ripening in which the fermentation process takes place.
- Still another application of Lactobacillus in the production of food products is the brining of vegetables such as cabbage (sauerkraut), carrots, olives or beets. Here the natural fermentation process can be controlled by the addition of an appropriate Lactobacillus starter culture.
- The application of Lactobacillus in food products is often associated with several health effects, see for example A. C. Ouwehand et al. in Int. Dairy Journal 8 (1998) 749-758. In particular the application of products is associated with several health effects for example relating to gut well being such as IBS (Irritable Bowel Syndrome), reduction of lactose maldigestion, clinical symptoms of diarrhoea, immune stimulation, anti-tumour activity and enhancement of mineral uptake.
- WO 99/23221 discloses multivalent antigen binding proteins for inactivating phages. The hosts may be lactic acid bacteria which are used to produce antibody binding fragments which are then harvested and used. WO 99/23211 discloses adding the harvested antibody fragments to provide anti-diarrhoea effects.
- WO 00/65057 is directed to the inhibition of viral infection using monovalent antigen-binding proteins. The antigen-binding protein may be a heavy chain variable domain derived from an immunoglobulin naturally devoid of light chains, such as those derived from Camelids as described in WO 94/04678. WO 00/65057 discloses transforming a host with a gene encoding the monovalent antigen-binding proteins. Suitable hosts can include lactic acid bacteria. This disclosure relates to the field of fermentation processing and the problem of phage infection which hampers fermentation. Specifically, llama VHH fragments per se are used to solve the problem of phage infection by neutralising Lactoccoccus lactis bacteriophage P2.
- Both WO 00/65057 and WO 99/23221 involve the use of antibody fragments harvested from a bacterial expression system.
- U.S. Pat. No. 6,605,286 is directed to the use of gram positive bacteria to deliver biologically active polypeptides, such as cytokines, to the body. U.S. Pat. No. 6,190,662 and
EP 0 848 756 B1 are directed to methods for obtaining surface expression of a desired protein or polypeptide. Monedero et al 2004 is directed to in-vitro studies on the use of single-chain antibodies (scFv) expressed by L. casei which recognise the VP8 and fraction of rotavirus outer capsid and blocks rotavirus infection in vitro. However, none of these documents disclose the use of heavy chain immunoglobulins or fragments of the VHH or VNAR type or domain antibodies. - One major disadvantage of these known systems is that the use of antibodies or antibody fragments per se (i.e. a harvested protein) in the treatment of a disease in a human may result in the antibody being degraded or digested before they provide the desired health benefits and even before they reach the desired location. Furthermore, it is often desirable to ensure that the antibody or antibody fragments are active in a specific region of the body. This will depend on the particular infection being treated.
- Enteropathogenic micro-organisms are micro-organisms which can produce disease in the intestinal tract. Examples of such micro-organisms include E. coli and Salmonella.
- Another example of an enteropathogen is rotavirus. Rotavirus continues to be the single most common cause of infantile diarrhoea in the world and most children get infected during the first 5 years of life. In developing countries, rotavirus induced diarrhoea may cause 600,000 to 870,000 deaths each year and in developed countries, rotavirus disease accounts for immense economic loss. Following the intussusception related withdrawal of the Rhesus rotavirus-tetravalent vaccine in July 1999, several strategies have been employed to try to develop a safe vaccine. Five oral live attenuated rotavirus vaccines are presently undergoing clinical trials for use in children, for example Barnes, G. L. et al. (1997). However, in particular in very young, malnourished children in developing countries the efficacy of such vaccinations might be limited. Several studies have also been conducted using passive immunotherapy, for example Offit, P. A. et al. (1985).
- Secretory immunoglobulins are implicated as a first line of defense against many mucosal pathogens, including rotavirus infection. Protection from clinical disease appears to rely mainly on the production of neutralizing antibodies against the outer capsid proteins VP4 or VP7 (Ruggeri, F. M. at al. (1998)); (Giammarioli, A-M. et al. (1996)). Recently however, non-neutralizing VP6 specific IgA antibodies have also been shown to inhibit rotavirus replication (Feng, N. et al. (2002)); Schwartz-Cornil, I. et al. (2002)). Both hyperimmune bovine colostrum and chicken egg yolks derived antibodies have previously been shown to be effective in the treatment of rotavirus diarrhoea (Davidson et al. (1989)); (Sarker, S. A., et al. (2001)). Successful treatment of rotavirus diarrhoea in children with immunoglobulin from immunized bovine colostrums has also been demonstrated (Sarker S. A. et al. (1998)). However, the high costs of production of these immunoglobulin preparations make their wide scale application as immunotherapeutics prohibitive.
- To date, no specific therapy is available for the widespread management of enteropathogenic micro-organisms and viruses. For example, the current management of rotavirus induced diarrhoea mainly involves prevention and oral rehydration. Thus, it is desirable to provide an alternative means for the management of enteropathogenic micro-organisms, by therapy and/or prophylaxis.
- The present invention is directed to a new method of therapy and/or prophylaxis of enteropathogenic micro-organisms.
-
- Acedo-Félix, E., & Pérez-Martinez, G. Significant differences between Lactobacillus casei subsp. casei ATCC 393T and commonly used plasmid-cured derivative revealed by a polyphasic study. Int. J. System. Evol. Microbiol. 53, 67-75 (2003).
- Barnes, G. L. et al. Phase I trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J. Paediatr. Child Health. 33, 300-304 (1997).
- Beck, C., et al. Beneficial effects of administration of Lactobacillus acidophilus in diarrhoeal and other intestinal disorders. Am. J. Gastroenterol. 35, 522-530 (1961).
- Bernstein, D., et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 354, 287-290 (1999).
- Boshuizen J A, Reimerink J H, Korteland-van Male A M, van Ham V J, Koopmans M P, Buller H A, Dekker J, Einerhand A W. Changes in small intestinal homeostasis, morphology, and gene expression during rotavirus infection of infant mice. J. Virol. 77, 13005-16 (2003).
- Clemens-Mann, M-L., et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for
serotypes - Cook, S. M. et al. Global seasonality of rotavirus infections. Bull WHO. 68, 171-177 (1990).
- Davidson et al., “Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus” Lancet (1989) 334:709-712.
- Desmyter, A., Decanniere, K., Muyldermans, S., & Wyns, L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 276, 26285-26290 (2001).
- Dooley et al. “Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display” Molecular Immunology (2003) 40, 25-33.
- Feng, N. et al. Inhibition of rotavirus replication by a non-neutralizing rotavirus VP6-specific IgA mAb. J. Clin. Invest. 109, 1203-1213 (2002).
- Frenken, L. G. J., et al. Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol. 78, 11-21 (2000).
- Ghahroudi, M. A., Desmyter, A., Wyns, L., Hamers, R. & Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414, 521-526 (1997).
- Giammarioli, A-M., Mackow, E. R., Fiore, L., Greenberg, H. B. & Ruggeri, F. M. Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. Virol. 225, 97-110 (1996).
- Guarino, A. et al. Enteral immunoglobulins for treatment of protracted rotaviral diarrhoea. Pediatr. Infect. Dis. J. 10, 612-614 (1991).
- Hamers-Casterman C., et al. Naturally occurring antibodies devoid of light-chains. Nature. 363, 446-448 (1993).
- Holt, L. J. et al. Domain antibodies: proteins for therapy. Trends in Biotechnology (2003) Vol. 21, No. 11: 484-490.
- Isolauri, E., Joensuu, J., Soumalainen, H., Luomala, M. & Vesikari, T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 13, 310-312 (1995).
- Kirkwood, C. D., Jim Buttery. Rotavirus vaccines—an update., Expert Opin Biol Ther. 3(1), 97-105 (2003).
- Krüger, C., et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nature Biotechnol. 20, 702-706 (2002).
- Krüger, C., Hultberg, A., Marcotte, H., Hermans, P., Frenken, L. G. J. & Hammarström, L. Passive immunization against caries using llama derived VHH fragments against Streptococcus mutans. (submitted)
- Nuttall et al. “Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70” Eur. J. Biochem. (2003) 270, 3543-3554.
- Nuttall et al. “Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1” Proteins: Structure, Function and Bioinformatics (2004) 55, 187-197).
- Ma, J. K., Smith, C. R., & Lehner, T. Use of monoclonal antibodies in local passive immunization to prevent colonization of human teeth by Streptococcus mutans. Infect Immun. 55, 1274-1278 (1987).
- Maassen, C. B., et al. Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine. 17, 2117-2128 (1999).
- Mastretta, E., et al. Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J. Pediatr. Gastroenterol. Nutr. 35, 527-531 (2002).
- Mondero et al. Selection of single-chain antibodies against the VP8 Subunit of rotavirus VP4 outer capsid protein and their expression in L. casei. Applied and Environmental Microbiology No. 4 (2004) 6936-6939.
- Offit, P. A. et al. Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies. J. Virol. 54, 58-64 (1985).
- Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 11, 305-312 (1999).
- Parashar, U. D., Hummelman, E. G., Bresee, J. S., Miller, M. A., Glass, R I. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9, 565-572 (2003).
- Perdigon, G., de Marcias, M. E., Alvarez, S., Oliver, G. & de Ruiz Holgado, A. P. Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and Lactobacillus acidophilus. Immunology. 63, 17-23 (1988).
- Pouwels, P. H., Leer, R. J. & Boersma, W. J. The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J. Biotechnol. 44, 183-192 (1996).
- Ruggeri, F. M., Johansen, K., Basile, G., Kraehenbuhl, J-P. & Svensson, L. Antirotavirus Immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhoea. J. Virol. 72, 2708-2714 (1998).
- Sarker, S. A., et al. Successful treatment of rotavirus diarrhoea in children with immunoglobulin from immunized bovine colostrum. Pediatr. Infect. Dis. J. 17, 1149-1154 (1998).
- Sarker, S. A., et al. Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhoea. J. Pediatr. Gastroenterol. Nutr. 32, 19-25 (2001).
- Schwartz-Cornil, I., Benureau, Y., Greenberg, H., Hendrickson, B. A. & Cohen, J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J. Virol. 76, 8110-8117 (2002).
- Svensson, L., Finlay, B. B., Bass, D., von Bonsdorff, C. H. & Greenberg, H. B. Symmetric infection of rotavirus on polarized human intestinal epithelial (Caco-2) cells. J. Virol. 65, 4190-4197 (1991).
- van der Linden, R. H. et al. Comparison of physical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta. 1431, 37-46 (1999).
- Weekly epidemiological record. Rotavirus vaccines. World Health Organization 74, 33-40 (1999).
- Weiner, C., Pan, Q., Hurtig, M., Boren, T., Bostwick. E. & Hammarström, L. Passive immunity against human pathogens using bovine antibodies. Clin. Exp. Immunol. 116, 193-205 (1999).
- Zimmerman, C. M., Bresee, J. S., Parashar, U. D., Riggs, T. L., Holman, R. C. & Glass, R. I. Cost of diarrhoea-associated hospitalizations and outpatient visits in an insured population of young children in the United States. Pediatr. Infect. Dis. J. 20, 14-19 (2001).
- According to a first aspect of the invention, there is provided a delivery system for delivering antibodies to the GIT comprising heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, wherein the immunoglobulins or fragments thereof are active in the gut.
- According to a second aspect of the invention, there is provided an expression vector comprising the gene encoding for the heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof.
- According to a third aspect, there is provided a micro-organism, preferably Lactobacillus, transformed with the above expression vector.
- According to a fourth aspect, there is provided a method for delivering antibodies to the gut in the treatment of enteropathogenic micro-organism infections using a micro-organism transformed with the gene encoding for heavy chains immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, comprising the steps of:
- i) transforming the micro-organism with an expression vector comprising heavy chain immunoglobulins of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof; and
ii) administering the transformed micro-organism to the gut of the human or animal in need of therapy such that the heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, are expressed and/or secreted in the gut. - According to a fifth aspect of the invention, there is provided the use of heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, or the delivery system as described above in therapy.
- According to a sixth aspect of the invention, there is provided heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, or the delivery system as described above in the manufacture of a medicament for the treatment of enteropathogenic micro-organism infections, preferably rotaviral infection.
- Further embodiments include a food product comprising a delivery system for delivering antibodies to the GIT wherein the antibodies are active in the gut and a pharmaceutical preparation comprising a delivery system for delivering antibodies to the GIT wherein the antibodies are active in the gut and the antibodies are heavy chain immunoglobulins of the VHH or VNAR type or fragments thereof, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof.
- According to a another aspect of the invention, there is provided a method for making a food product or pharmaceutical preparation comprising adding the delivery system to the food product or pharmaceutical preparation during the manufacture of the food product or pharmaceutical preparation.
- According to another aspect of the invention, there is provided the use of the food product or pharmaceutical preparation as described above to deliver health benefits to the gut of a subject.
- In the detailed description of the embodiments of the invention, reference is made to the following figures.
-
FIGS. 1 a and b shows that rotavirus specific VHH particles neutralise rotavirus in-vitro. -
FIG. 2 shows that rotavirus specific VHH particles neutralise rotavirus in-vivo. -
FIG. 3 shows a Map of Lactobacillus expression vectors: -
- (a) 2A10-anchor;
- (b) VHH1-anchor, mediating surface-anchored expression of antibody fragments by fusion to the last 244 amino acids of L. casei proteinase P;
- (c) 2A10-secreted; and
- (d) VHH1-secreted with a stop codon (TAA) inserted after the E-tag sequence, mediating secretion of the antibody fragment.
- Tldh: transcription terminator of the lactate dehydrogenase gene of L. casei; deleted Tld:, remaining sequence after deletion of Tldh;
- 2A10-scFv: single-chain antibody against VP4/VP7;
- VHH1: heavy chain antibody fragment against rotavirus; long anchor, anchor sequence from the proteinase P gene of L. casei (244 amino acids);
- Tcbh: transcription terminator sequence of the conjugated bile acid hydrolase gene of
L. plantarum 80; - Pldh: Promotor sequence of the lactate dehydrogenase gene of L. casei, SS PrtP; signal sequence of the PrtP gene (33 aa), N-terminus PrtP, N-terminus (36 amino cids) of the PrtP gene;
- Ampr: ampicillin-resistance gene;
- Ery: erythromycin-resistance gene;
- Rep: repA gene of plasmid p353-2 from L. pentosis;
- Ori: origin of replication (Ori+=ori E. coli, Ori-=ori Lactobacillus).
- Arrows: indicate a stop codon.
-
FIG. 4 a shows the results of Flow cytometry showing the expression of 2A10-scFv (light grey) and VHH1 (dark grey) on the surface of the Lactobacillus paracasei by detection of the E-tag by a mouse anti-E-tag antibody (b) Scanning electron microscope (SEM) picture showing the binding of rotavirus by the VHH1 surface expressing Lactobacillus paracasei. -
FIG. 5 shows in vitro neutralization assay results which test efficacy of lactobacilli expressing VHH1-anchored fragments to inhibit rotavirus infection of MA104 cells. Reduction of infection to 60% or more was considered to be specific neutralization. The solid line represents neutralization level achieved by lactobacilli produced E-tag purified VHH1 antibody (20 μg/ml). Dotted line indicates the neutralization level of 2A10 monoclonal hybridoma supernatant (147 ng/ml). Neutralization achieved by different concentrations of VHH1 anchored lactobacilli (▪), 2A10 anchored lactobacilli () and non-transformed lactobacilli (□). -
FIG. 6( a) shows the prevalence of diarrhoea in mice treated with lactobacilli expressing VHH1-anchored fragments. Pooled results of three experiments (b) Prevalence of diarrhoea in mice treated with lactobacilli surface expressing 2A10-scFv. Pooled results from three experiments. -
FIG. 7 shows duodenum and jejunum sections from pups treated with different formulations, stained with hematoxylin and eosin. The bar represents 100 μm length. -
FIG. 8 shows the load of vp7 RNA in small intestinal tissue samples as determined by real time PCR. -
FIG. 9 shows evaluation of different doses of lactobacilli expressing VHH1-anchored fragments and their efficacy to reduce diarrhea. -
FIG. 10 shows evaluation of lactobacilli expressing VHH1-anchored fragments in a freeze-dried form. -
FIG. 11 shows scanning electron microscope (SEM) picture showing the binding of rotavirus by the VHH1 surface expressing Lactobacillus paracasei. -
FIG. 12 shows an alignment of the VHH's having affinity for Rotavirus viral particles. - The invention will now be described by way of example, by a series of embodiments.
- In general, the present invention is directed to the delivery of heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, to the gastro-intestinal tract (GIT) which are suitable for use in the management of infection by enteropathogenic micro-organisms.
- The present invention is also directed to a food product or pharmaceutical composition comprising a delivery system for delivering antibodies to the GIT wherein the antibodies are active in the gut.
- Heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, may be obtained using techniques well known in the art. Preferably, the immunoglobulins or fragments thereof have the following characteristics:
-
- i) They show good binding affinity and the desired inhibition functionality under the conditions present in the GIT; and
- ii) They have good proteolytic stability in that they are stable against degradation by proteolytic enzymes.
- Preferably, the heavy chain immunoglobulin or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, are specific to an enteropathogenic micro-organism.
- Van der Linden, R. H., et al. “Comparison of physical properties of llama VHH antibody fragments and mouse monoclonal antibodies” Biochim. Biophys. Acta (1990) 1431, 37-46 obtained heavy chain antibodies with a high specificity and affinity against a variety of antigens. Furthermore, heavy chain immunoglobulins are readily cloned and expressed in bacteria and yeast as shown in Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21. Methods for the preparation of such immunoglobulins or fragments thereof on a large scale comprising transforming a mould or a yeast with an expressible DNA sequence encoding the antibody or fragment are also described in WO 94/25591 in the name of Unilever. Finally, EP-A-0584421 describes heavy chain immunoglobulin regions obtained from Camelids. Nuttal et al. (2003 and 2004) and Dooley et al. (2003) describe the isolation of various VNAR antibodies. Holt et al. (2003) describes the isolation and characteristics of domain antibodies (dAbs) which have similar properties to VHH immunoglobulins.
- Preferably, the antibodies may be llama heavy chain antibodies, more preferably VHH antibodies or fragments thereof. In 1993, Hamers-Casterman et al. discovered a novel class of IgG antibodies in Camelidae i.e. camels, dromedaries and llamas. (“Naturally occurring antibodies of devoid light-chains” Nature (1993) 363, 446-448). Heavy chain antibodies constitute about one fourth of the IgG antibodies produced by the camelids, llamas. These antibodies are formed by two heavy chains but are devoid of light chains. The variable antigen binding part is referred to as the VHH domain and it represents the smallest naturally occurring, intact, antigen-binding site (Desmyter, A., et al. “Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody” J. Biol. Chem. (2001) 276, 26285-26290). Heavy chain antibodies with a high specificity and affinity can be generated against a variety of antigens and they are readily cloned and expressed in bacteria and yeast (Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21). Their levels of expression, solubility and stability are significantly higher than those of classical F(ab) or Fv fragments (Ghahroudi, M. A. et al “Selection and identification of single domain antibody fragments from camel heavy-chain antibodies” FEBS Lett. (1997) 414, 521-526).
- Another good source of heavy chain antibodies can be found in sharks. It recently has been shown that sharks also have a single VH-like domain in their antibodies termed VNAR (Nuttall et al. “Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70” Eur. J. Biochem. (2003) 270, 3543-3554; Dooley et al. “Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display” Molecular Immunology (2003) 40, 25-33; Nuttall et al. “Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1” Proteins: Structure, Function and Bioinformatics (2004) 55, 187-197). Fragments of the VNAR-type immunoglobulin can be used.
- Holt et al, “Domain antibodies:proteins for therapy” Trends in Biotechnology (2003):Vol. 21, No. 11:484-490, reviews antigen-binding fragments called “domain antibodies” or dAbs which comprise only the VH or VL domain of an antibody and are consequently smaller than, for example, Fab and scFv. DAbs are the smallest known antigen-binding fragments of antibodies, ranging from 11 kDa to 15 kDa. They are highly expressed in microbial cell culture. Each dAb contains three of the six naturally occurring complementarity determining regions (CDRs) from an antibody.
- The immunoglobulin may be multivalent, i.e. bivalent, trivalent, tetravalent, in that it comprises more than one antigen binding site. The antigen binding sites may be derived from the same parent antibody or fragment thereof or from different antibodies which bind the same epitope. If all binding sites have the same specificity then a monospecific immunoglobulin is produced. Alternatively a multispecific immunoglobulin may be produced binding to different epitopes of the same antigen or even different antigens.
- The immunoglobulin or fragment thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, may be naturally occurring i.e. elicited in vivo upon immunizing an animal with the desired antigen or synthetically made, i.e. obtained by genetic engineering techniques.
- The antibody or fragment thereof may be naturally occurring or may be obtained by genetic engineering using techniques well known in the art.
- The antibody can be chosen to be active against many different antigens, including micro-organisms, larger parasites, viruses and bacterial toxins.
- Functional equivalents to VHH, VNAR and dAbs are also contemplated. A functional equivalent means a sequence which shows binding affinity for an antigen similar to the full length sequence. For example, additions or deletions of amino acids which do not result in a change of functionality are encompassed by the term functional equivalents.
- Techniques for synthesising genes, incorporating them into micro-organism hosts and expressing genes in micro-organisms are well known in the art and the skilled person would readily be able to put the invention into effect using common general knowledge. The use of replicating or integrating vectors is contemplated.
- According to one embodiment of the present invention, a food product or pharmaceutical preparation comprises a delivery system for delivering antibodies to the GIT wherein the antibodies are heavy chain immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and they are active in the gut. Preferably, the delivery system is a micro-organism and the immunoglobulins are llama derived antibodies or fragments thereof. We have surprisingly found that these transformed micro-organisms will express llama heavy chain antibodies or fragments thereof on their surface and are able to reduce the viral load, normalize the pathology and mitigate the diarrhoea in an animal model of rotavirus infection. Furthermore, the llama heavy chain antibodies or fragments thereof were found to be very effective in reducing infection both in in vitro and in vivo models of rotavirus infection.
- The use of fragments or portions of a whole antibody which can nevertheless exhibit antigen binding affinity is also contemplated. Fragments should preferably be functional fragments. A functional fragment of a heavy chain means a fragment of a heavy chain of an immunoglobulin which fragment shows binding affinity for an antigen similar to the full length sequence. Binding affinity is present when the dissociation constant is more than 10exp5. Such a fragment can be advantageously used in therapy, for example, as it is likely to be less immunogenic and, if needed, is more able to penetrate tissues due to its smaller size.
- The antibodies are suitable for delivery to the GIT and must be able to be active in the stomach and/or gut. One advantage of the delivery system of the present invention includes that in vivo production or release of heavy chain immunoglobulin or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach.
- In order to determine whether an immunoglobulin or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, will be suitable for use in the present invention the following test may be applied.
- The antibody produced is selected under specific conditions of low pH, preferably from 1.5 to 3.5, and in the presence of pepsin (a protease abundant in the stomach) to result in highly beneficial molecules that work well in the GIT and are suitable for use according to the present invention.
- The present application is applicable to the management of enteropathogenic micro-organisms in general. Preferably, the invention is directed to the management of enteropathogenic viruses and/or enteropathogenic bacteria. Management is understood to include therapy and/or prophylaxis.
- Enteropathogenic bacteria may include, for example, Salmonella, Campilobacter, E. coli or Helicobacter. Enteropathogenic viruses may include, for example, Norovirus (Norwalk like virus), enteric adenovirus, Coronavirus, astroviruses, caliciviruses, and parvovirus. Rotavirus and the Norwalk family of viruses are the leading causes of viral gastroenteritis, however, a number of other viruses have been implicated in outbreaks. Most preferably, the present invention is directed the management of rotaviral infection.
- The present application may also be used in the management of other non-enteropathogenic viruses like Hepatitis.
- Alternatively, the delivery system may comprise a probiotic micro-organism. The probiotic micro-organism should preferably be able to survive passage in the GIT and should be active in the stomach/gut. Preferably, the micro-organism should be able to undergo transient colonization of the GIT; be able to express the gene in the GIT; and be able to stimulate the gut immune system.
- Examples of suitable probiotic micro-organisms include yeast such as Saccharomyces, Debaromyces, Kluyveromyces and Pichia, moulds such as Aspergillus, Rhizopus, Mucor and Penicillium and bacteria such as the genera Bifidobacterium, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Oenococcus and Lactobacillus.
- Specific examples of suitable probiotic micro-organisms are:
- Kluyveromyces lactis, Kluyveromyces fragilis, Pichia pastoris, Saccharomyces cerevisiae, Saccharomyces boulardii, Aspergillus niger, Aspergillus oryzae, Mucor miehei, Bacillus subtilis, Bacillus natto, Bifidobacterium adolescentis, B. animalis, B. breve, B. bifidum, B. infantis, B. lactis, B. longum, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Lactobacillus acidophilus, L. brevis, L. casei, L. delbrueckii, L. fermentum, L. gasseri, L. helveticus, L. johnsonii, L. lactis, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. sakei, L. salivarius, Lactococcus lactis, Lactococcus cremoris, Leuconostoc mesenteroides, Leuconostoc lactis, Pediococcus acidilactici, P. cerevisiae, P. pentosaceus, Propionibacterium freudenreichii, Propionibacterium shermanii and Streptococcus salivarius.
- Particular probiotic strains are:
- Saccharomyces boulardii, Lactobacillus casei shirota, Lactobacillus casei immunitas, Lactobacillus casei DN-114 001, Lactobacillus rhamnosus GG (ATCC53103), Lactobacillus reuteri ATCC55730/SD2112, Lactobacillus rhamnosus HN001, Lactobacillus plantarum 299v (DSM9843), Lactobacillus johnsonii La1 (I-1225 CNCM), Lactobacillus plantarum WCFS1, Bifidobacterium lactis HN019, Bifidobacterium animalis DN-173010, Bifidobacterium animalis Bb12, Lactobacillus casei 431, Lactobacillus acidophilus NCFM, Lactobacillus reuteri ING1, Lactobacillus salivarius UCC118, Propionibacterium freudenreichii JS, Escherichia coli Nissle 1917.
- Conveniently, the micro-organism may be a lactic acid bacterium. More, preferably, the micro-organism is chosen from either the genus Lactobacillus or Bifidobacterium. Even more preferably, the micro-organism is Lactobacillus. Particularly, the Lactobacillus is Lactobacillus casei 393 pLZ15. Lactobacillus casei has recently been reidentified as Lactobacillus paracasei (Perez-Martinez, 2003).
- The micro-organism may also be a probiotic Bacillus species, as described in Le H. Duc et al., Applied and Environmental Microbiology, 2004, p. 2161), and particularly preferred are Bacillus cereus, Bacillus clausii and Bacillus pumilus.
- A system based on probiotic bacteria represents a safe and attractive approach and represents one of the cheapest antibodies production systems. The wide scale application of the micro-organism, preferably Lactobacillus, expressing antibodies is relatively easy and requires minimal handling and storage costs and economical.
- Alternatively, the micro-organism may be a yeast. Suitable yeasts include the baker's yeast S. cerevisiae. Other yeasts like Candida boidinii, Hansenula polymorpha, Pichia methanolica and Pichia pastoris which are well known systems for the production of heterologous proteins and may be used in the present invention.
- Filamentous fungi, in particular species from the genera Trichoderma and Aspergillus have the capacity to secrete large amounts of proteins, metabolites and organic acids into their culture medium. This property has been widely exploited by the food and beverage industries where compounds secreted by these filamentous fungal species have been used for decades.
- It is understood that these micro-organisms may be genetically modified micro-organisms.
- The delivery system according to this aspect will comprise a micro-organism transformed with the gene encoding the heavy chain immunoglobulin or fragment thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof.
- Such a system based on probiotic bacteria represents a safe and attractive approach to delivering antibodies to the GIT. Probiotic bacteria are well known in the art and represent one of the cheapest antibodies production systems. Hence, the wide scale application of the lactobacilli expressing antibodies is relatively easy and requires minimal handling and storage costs. Furthermore, the probiotic bacteria are able to colonize the gut at least temporarily, for days, weeks or months, will remain in the gut for longer and enable the constant production of the antibody to enable more constant and prolonged protection against an enteropathogenic microorganism or virus.
- The present invention is based on the findings that heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, of the invention may be used in the therapy or prophylaxis of infection by enteropathogenic micro-organisms.
- More specifically, the immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, may be used in the therapy or prophylaxis of viral gastroenteritis or diarrhoea caused by rotavirus.
- A further advantage of the present invention is that the use of probiotic micro-organisms expressing immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, enables the micro-organism, for example Lactobacillus, to provide the normal health benefits associated with this probiotic micro-organism, together with the prophylactic/therapeutic benefits in the management of the infection to be treated. This “dual effect” therapy provides synergistic effects and therefore greater health benefits to the subject than known in the art.
- In accordance with one embodiment of the present invention, the heavy chain immunoglobulins or functional fragments thereof of the VHH type are derived from camelids, including llama and camels. An alternative source of heavy chain antibodies can be found in sharks. It recently has been shown that sharks also have a single VH-like domain in their antibodies termed VNAR. Fragments of VNAR-type immunoglobulin can be used in accordance with the present invention. Functional equivalents as described before are also contemplated. Alternatively, domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, may be used.
- Preferably, the immunoglobulins are llama derived heavy chain antibodies or fragments thereof. Many llama derived heavy chain antibody fragments have been disclosed in the art. More preferred is the heavy chain immunoglobulin or fragment thereof which shows binding affinity with a dissociation constant of at least 10
exp 5 for rotavirus, especially rotavirus strains Wa, CK5, Wa1, RRV or CK5. - Llama heavy chain antibodies are particularly advantageous as they have surprisingly been found to be very effective in the treatment of rotaviral infection. Llama VHH antibody fragments have surprisingly been found to reduce the viral load, normalize the pathology and mitigate diarrhoea during rotavirus infection.
- Particularly preferred LLama derived VHH sequences having affinity of rotavirus are provided by this specification in the sequence listing, SEQ ID No's 1 to 21. Alternatively, VHH sequences having at least 70%, 80%, 85%, 90%, 95%, 98% or 99% amino acid identity with SEQ ID No. 1 and having affinity for a rotavirus particle or antigen are also preferred embodiments according to this invention. VHH sequences may be derived from camellids, via immunization and/or by screening for affinity, but may also be derived from other mammalian species such as mice or humans and/or be camelized by amino acid substitutions, as described in the art. In another embodiment, the VHH sequences may be fused to yield multimeric units of 2, 3, 4, 5 or more VHH units, optionally linked via a spacer molecule. In another embodiment, several VHH sequences may be combined, separately or in one multimeric molecule. Preferably the VHH sequences have different specificities, for instance VHH sequences may be combined to provide a wide spectrum of affinities for a particular pathogen. In a highly preferred embodiment, 2, 3, 4, 5 or more VHH sequences having affinity for any one of rotavirus strains Wa, CK5, Wa1, RRV or CK5, may be combined, as separate monomeric units or as combined units on a carrier, for instance on a probiotic bacterium and/or on a multimeric molecule.
- Furthermore, llama heavy chain antibodies have also unexpectedly been found to be suitable for administration in the GIT. Llama heavy chain antibodies were found to be highly resistant to protease degradation in the stomach and to withstand the acidic environment of the stomach. This is despite the fact that the proteolytic system in the GIT is more aggressive an environment than, for example encountered in the mouth. Activity in the gut is hampered by proteolytic activity, including protease and peptidase. We have now found that even more surprisingly the in vivo production or release of antibody fragments locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach and gut. The present invention is the first system which enables expression of antibodies in the GIT which are suitable for the management of rotavirus infection.
- When probiotic micro-organisms are chosen as the delivery system, we have found that these transformed micro-organisms will express llama heavy chain antibodies or fragments thereof on their surface and are able to reduce the viral load, normalize the pathology and mitigate the diarrhoea in an animal model of rotavirus infection.
- The llama heavy chain antibodies are then expressed by the micro-organism in the GIT. Expression of the llama derived VHH antibody fragment may be both on the surface of the micro-organism and/or as a secreted protein of the micro-organism. Preferably secreted forms of the VHH antibody fragment is in multimeric form to enhance aggregation and clearance of the viral load.
- Preferably, the micro-organism or more preferably a probiotic bacterium is transformed with an expression vector comprising the gene for the llama heavy chain antibody or fragments thereof. The expression vector may contain a constitutive promoter in order to express the antibodies or fragments thereof. Such a constitutive promoter will support in situ expression of antibodies by transformed lactobacilli persisting (at least for a short period) in the intestinal tract after administration. Alternatively, the promoter may be chosen to be active only in the GIT and/or stomach/gut i.e. suitable for GIT specific expression only. This will ensure expression and/or secretion of the llama heavy chain antibody or fragments thereof in the GIT, preferably the gut. Many constitutive promoters for lactobacilli are known in the art and an example of a promoter that is specifically inducible in the GIT is Pldh (Pouwels et al “Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens” Methods in Enzymology (2001) 336:369-389).
- The expression vectors described in the examples are able to replicate in the transformed lactobacilli and express the antibodies of fragments thereof. It will be understood that the present invention is not limited to these replication expression vectors only. The whole expression cassette can be inserted in a so-called “integration” plasmid, whereby the expression cassette will be integrated into the chromosome of the lactobacilli after transformation, as known in the art (Pouwels, P. H. and Chaillou, S. Gene expression in lactobacilli (2003) Genetics of lactic acid bacteria page 143-188).
- According to an alternative embodiment, if encapsulation is chosen as the delivery system, the encapsulation method should survive passage to the stomach through the GIT and should be able to provide a sustained release of the antibody over a set period of time. This will ensure that the llama heavy chain antibody or fragment is delivered over time to the stomach. Llama heavy chain antibodies or VHH or VNAR fragments, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, are particularly suitable for this encapsulation method due to their ability to survive in the gut when released.
- According to this embodiment of the present invention, delivery of the antibodies to the GIT can be effected by the use of encapsulates, such as those known in the food and pharmaceutical industries. Natural biopolymers may be used. Examples include Ca-alginate, carrageenan, gellan gum or gelatine. The delivery system may be an encapsulation method known in the art which will deliver the immunoglobulin or fragments thereof specifically to the gut. The encapsulate must therefore be able to survive until entry to the gut and then be released. Such a delivery system comprises a general protective system that protects the antibodies from degradation. Such techniques may include liposome entrapment, spinning disk and coacervation. Any trigger can be used to prompt the release of the encapsulated ingredient, such as pH change (enteric coating), mechanical stress, temperature, enzymatic activity. These techniques are expanded on in the article by Sebastien Gouin “Microencapsulation: industrial appraisal of existing technologies and trends” Food Science and Technology (2004) 15: 330-347. Preferably, an enteric coating is used. Additionally, the encapsulation method may allow the slow release of the antibody in the gut and/or stomach. This will enable a constant release of the antibody or functional fragment or equivalent over a set period of time.
- The llama heavy chain antibodies or fragments thereof may be used in the therapy or prophylaxis of viral infection, such as viral gastroenteritis or rotavirus infection.
- Specifically, the antibodies may be delivered to the GIT using a micro-organism transformed with llama heavy chain antibodies comprising the steps of i) transforming the micro-organism with the gene encoding llama heavy chain antibodies; and ii) administering the transformed micro-organism to the GIT of the human or animal in need of therapy.
- The delivery system may comprise a micro-organism transformed with antibodies or fragments thereof the antibodies are expressed and/or secreted in the gut. Hence, use of a micro-organism as the delivery system has the advantages that in vivo production of antibody fragments locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach. Such a system based on probiotic bacteria represents a safe and attractive approach to delivering antibodies to the GIT. Hence, the wide scale application of the lactobacilli expressing antibodies is relatively easy and requires minimal handling and storage costs and economical. Furthermore, the probiotic bacteria will remain in the gut for longer and enable the constant production of the antibody to enable more constant protection against the enteropathogenic microorganism.
- Advantageously the amount of the micro-organism in food products of the invention is between 106 and 1011 per serving or (for example if serving size is not known) between 106 and 1011 per 100 g of product, more preferred these levels are from 108 to 109 per serving or per 100 g of product.
- The antibodies for use according to the present invention must be active in the gut/stomach, i.e. they must be functional and retain their normal activity including inactivating their target. The active antibodies according to the invention should bind to their target as normal, thus, the binding affinity of the antibody for the antigen should be as normal. Binding affinity is present when the dissociation constant is more than 105.
- Hence, the food product or pharmaceutical preparation according to the invention will be able to selectively address a specific disease or symptom of a disease. The choice of antibody will determine the disease or symptom to be treated or reduced.
- It will be understood that when the product is a food product any antibody may be used. However, when the product is a pharmaceutical preparation heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof are preferred.
- Preferably, the antibody or fragments thereof should have one or more of the following characteristics:
- i) They show good binding affinity and the desired inhibition functionality under the conditions present in the G/I tract; and
ii) They have good proteolytic stability in that they are stable against degradation by proteolytic enzymes.
iii) The antibodies should be thermostable which enables their inclusion in a variety of food products. The food products may be prepared in a process requiring pasteurization and it is preferred that the activity of the antibodies is largely maintained despite heat treatment. - The antibody or fragment thereof should be able to be expressed and secreted in the gut. Several assays are well known in the art which mimic GIT conditions and are used for instance to select suitable probiotics that can survive GIT conditions. A suitable assay for determining whether an antibody can survive the GIT conditions is described by Picot, A. and Lacroix, C. (International Dairy Journal 14 (2004) 505-515).
- In order to determine whether an antibody will be suitable for use in the present invention the following test may be applied. The antibody produced is selected under specific conditions of low pH, preferably from 1.5 to 3.5, and in the presence of pepsin (a protease abundant in the stomach) to result in highly beneficial molecules that work well in the G/I tract and are suitable for use according to the present invention.
- The present application may be applicable to the management of enteropathogenic micro-organisms in general. Enteropathogenic micro-organisms include viruses or enteropathogenic bacteria. Management is understood to mean therapy and/or prophylaxis.
- One further embodiment of the invention is a food product or pharmaceutical preparation containing the delivery system described above. Several food products may be prepared according to the invention, for example meal replacers, soups, noodles, ice-cream, sauces, dressing, spreads, snacks, cereals, beverages, bread, biscuits, other bakery products, sweets, bars, chocolate, chewing gum, diary products, dietetic products e.g. slimming products or meal replacers etc. For some applications food products of the invention may also be dietary supplements, although the application in food products of the above type is preferred.
- Table 1 indicates a number of products, which may be prepared according to the invention, and a typical serving size.
-
TABLE 1 Product Serving Size margarine 15 g ice-cream 150 g dressing 30 g sweet 10 g bar 75 g meal replacer drink 330 ml beverages 200 ml - An alternative means of administration of the delivery system comprising a micro-organism transformed with antibodies or functional fragments thereof comprises a dispensing implement for administering food which contains a coating of the delivery system on at least one of its surfaces. The term dispensing implement covers tube, straws, spoons or sticks or other implements which are used to deliver a liquid or semi-solid food product to a consumer. The dispensing implement may also be used to deliver a solid food product to a consumer. This dispensing tube or straw is especially suitable for use with certain beverages where high or low pH and/or temperature means that direct addition of the micro-organism to the beverage is not recommended
- The dispensing implement can also be used when the delivery system of the invention comprises encapsulated antibodies or even with antibodies per se.
- The dispensing implement contains on at least one surface a coating of the micro-organism, encapsulated antibodies or antibodies per se After the dispensing implement is coated with these particles, the implement is stored in an outer envelope which is impermeable to moisture and other contamination. The coating material which contains these particles is non-toxic to humans and to bacteria and can be an oil such as corn oil or a wax. This aspect is described in U.S. Pat. No. 6,283,294 B1. Once the dispensing implement containing these particles penetrates the beverage or semi-solid food product, the particles are integrated into the food product, giving a desirable dose of the antibodies with a serving of the product.
- Preferably, the encapsulated particle, antibody per se or the micro-organism may be suspended in water which is then applied to the dispensing implement and evaporated. By using this method the dispensing implement will have a coating of the encapsulated particle, antibody per se or the micro-organism, which can then be released when the dispensing implement comes into contact with the liquid or semi-solid food product.
- A still further embodiment of the invention relates to a method for making a food product or pharmaceutical preparation comprising a delivery system for delivering antibodies to the GIT wherein the antibodies are active in the gut comprising adding the delivery system to the food product or pharmaceutical preparation during the manufacture of the food product.
- It is essential that the micro-organism is alive in the product, thus, for example, if the product is heated during processing, the micro-organism has to be added after the heating step (post-dosing). However, if a product is fermented with the micro-organism, a heating step after the fermentation will not be acceptable. If the product is a liquid product, administration of the micro-organism could take place by use of a dispensing implement such as a drinking straw.
- A further embodiment of the invention relates to the use of the food product or pharmaceutical preparation comprising the delivery system according to the invention to deliver health benefits to the gut of a subject after administration. Such health benefits include the specific health benefit the antibody may provide. The micro-organism itself may also provide several health effects for example relating to gut well being such as IBS (Irritable Bowel Syndrome), reduction of lactose maldigestion, clinical symptoms of diarrhoea, immune modulation, anti-tumor activity, adjuvant effects and enhancement of mineral uptake.
- The food product or pharmaceutical preparation according to the present invention may be suitable for the management, including treatment or prophylaxis of infections caused by enteropathogenic bacteria or viruses. Other antibodies which may be incorporated into the invention will be able to provide a multitude of other health benefits.
- The present invention is based on the finding that heavy chain immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, of the invention may be used in the therapy or prophylaxis of infection by enteropathogenic micro-organisms. Furthermore, the immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, may be used in the therapy or prophylaxis of viral gastroenteritis or diarohoea caused by the enteropathogenic microorganism rotavirus.
- A further advantage of the present invention is that the use of food products or pharmaceutical preparations comprising probiotic micro-organisms expressing immunoglobulins or fragments thereof of the VHH- or VNAR-type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, enables the micro-organism, for example Lactobacillus, to provide the normal health benefits associated with this probiotic micro-organism, together with the prophylactic/therapeutic benefits in the management of the infection to be treated. This “dual effect” therapy provides greater health benefits to the subject than that known in the art.
- In accordance with another embodiment of the present invention, the heavy chain immunoglobulins or fragments thereof of the VHH type are derived from camelids, including llama and camels. Many llama derived heavy chain antibody fragments have been disclosed in the art. More preferred is the heavy chain immunoglobulin or fragment thereof which shows binding affinity with a dissociation constant of at least 10
exp 5 for rotavirus, especially rotavirus strains Wa, CK5, Wa1, RRV or CK5. - We have surprisingly found that llama heavy chain antibodies are effective in the management of rotavirus infection. When the antibodies used are llama heavy chain antibodies, the health benefit delivered will include an anti-diarhoeal effect. Hence, llama heavy chain antibodies can be used in the management of rotavirus infection, including the therapy or prophylaxis of rotavirus infection. We have found that llama VHH antibody fragments can reduce the viral load, normalize the pathology and mitigate diarrhoea during rotavirus infection. Rotavirus continues to be the single most common cause of infantile diarrhoea in the world and most children get infected during the first 5 years of life. In developing countries, rotavirus induced diarrhoea may cause 600,000 to 870,000 deaths each year and in developed countries, rotavirus disease accounts for immense economic loss.
- Furthermore, llama heavy chain antibodies have also unexpectedly been found to be suitable for administration in the gut. We have surprisingly found that the llama heavy chain antibodies were found to be highly resistant to protease degradation in the stomach and to withstand the acidic environment of the stomach. This is despite the fact that the proteolytic system in the gut/stomach is more aggressive an environment than, for example encountered in the mouth. The in vivo production of antibody fragments locally in the GIT circumvents the practical problem of degradation of orally administered antibodies in the stomach. The present invention is the first system which enables expression of antibodies in the GIT which are suitable for the management of rotavirus infection.
- Hence, the use of food products or pharmaceutical preparations comprising lactobacilli expressing llama heavy chain antibodies enables the lactobacilli to provide the normal health benefits associated with this probiotic together with the prophylactic/therapeutic benefits in the management of rotavirus infection. The present invention is the first system which enables expression of antibodies in the GIT which are suitable for the management of rotavirus infection.
- It will be understood that the food product or pharmaceutical preparation can be administered in order to deliver a health benefit to the subject and/or to combat a specific disease or infection. The choice of the antibody will depend on the disease to be treated.
- Preferably, the micro-organism is transformed with an expression vector comprising the gene for the llama heavy chain antibody or fragment thereof. Either an integrating or a replicating vector may be used.
- If encapsulation is chosen as the delivery system, the encapsulation method should survive passage to the stomach through the GIT and should be able to provide a sustained release of the antibody over a set period of time. This will ensure that the llama heavy chain antibody or fragment is delivered over time to the stomach. Llama heavy chain antibodies or heavy chains thereof are particularly suitable for this encapsulation method due to their ability to survive in the gut when released.
- Specifically, the antibodies may be delivered to the GIT using a micro-organism transformed with llama heavy chain antibodies comprising the steps of i) transforming the micro-organism with the gene encoding llama heavy chain antibodies; and ii) administering the transformed micro-organism to the GIT of the human or animal in need of therapy.
- Typically these are oil in water or water in oil emulsions, also spreads which are substantially fat free are covered. Typically these products are spreadable and not pourable at the temperature of use e.g. 2-10° C. Fat levels may vary in a wide range e.g. full fat margarines with 60-90 wt % of fat, medium fat margarines with 30-60 wt % of fat, low fat products with 10-30 wt % of fat and very low or fat free margarines with 0 to 10 wt % of fat.
- The fat in the margarine or other spread may be any edible fat, often use are soybean oil, rapeseed oil, sunflower oil and palm oil. Fats may be used as such or in modified form e.g. hydrogenated, esterified, refined etc. Other suitable oils are well known in the art and may be selected as desired.
- The pH of a margarine or spread may advantageously be from 4.5 to 6.5.
- Examples of spreads other than margarines are cheese spreads, sweet spreads, yogurt spreads etc.
- Optional further ingredients of spreads may be emulsifiers, colourants, vitamins, preservatives, gums, thickeners etc. The balance of the product will normally be water.
- A typical size for an average serving of margarine or other spreads is 15 grams. Preferred VHH-producing Lactobacillus in the margarine or spread are 106 and 1011 per serving most preferred 108 to 1010 per serving. The Lactobacillus strain has to be added aseptically after the heating steps in the process. Alternatively, encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 μg per serving is added, more preferably between 50 and 500 μg are added per serving. Most preferably two or three servings are given each day.
- For the purpose of the invention the term frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
- Preferably the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 3 wt %, more preferred from 10 to 70 wt %, for example 40 to 70 wt %.
- Ice-cream will typically comprise 2 to 20 wt % of fat, 0 to 20 wt % of sweeteners, 2 to 20 wt % of non-fat milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water. Typically ice-cream will be aerated e.g. to an overrun of 20 to 400%, more general 40 to 200% and frozen to a temperature of from −2 to −200° C., more general −10 to −30° C. Ice-cream normally comprises calcium at a level of about 0.1 wt %.
- A typical size of an average serving of frozen confectionary material is 150 grams. Preferred Lactobacillus levels are from 106 and 1011 per serving, more preferred these levels are from 107 to 1010 per serving most preferred 108 to 109 per serving. The Lactobacillus strain has to be added aseptically after the heating steps in the process. Alternatively, encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 μg per serving is added, more preferably between 50 and 500 μg are added per serving. Most preferably two or three servings are given each day.
- Beverages, for example Tea Based Products or Meal Replacers
- Lactobacillus can advantageously be used to beverages for example fruit juice, soft drinks etc. A very advantageous beverage in accordance to the invention is a tea based product or a meal replacers drink. These products will be described in more detail herein below. It will be apparent that similar levels and compositions apply to other beverages comprising vitamin producing Lactobacillus bacteria.
- For the purpose of this invention the term tea based products refers to products containing tea or tea replacing herbal compositions e.g. tea-bags, leaf tea, herbal tea bags, herbal infusions, powdered tea, powdered herbal tea, ice-tea, ice herbal tea, carbonated ice tea, carbonated herbal infusion etc.
- Typically some tea based products of the invention may need a preparation step shortly before consuming, e.g. the making of tea brew from tea-bags, leaf tea, herbal tea bags or herbal infusions or the solubilisation of powdered tea or powdered herbal tea. For these products it is preferred to adjust the level of Lactobacillus in the product such that one serving of the final product to be consumed has the desired levels of Lactobacillus as described above.
- For ice-tea, ice herbal tea, carbonated ice tea, carbonated herbal infusions the typical size of one serving will be 200 ml or 200 grams.
- Meal replacer drinks are typically based on a liquid base which may for example be thickened by means of gums or fibres and whereto a cocktail of minerals and vitamins are added. The drink can be flavoured to the desired taste e.g. fruit or choco flavour. A typical serving size may be 330 ml or 330 grams.
- Both for tea based beverages and for meal replacer drinks, preferred Lactobacillus levels are 106 and 1011 per serving, more preferred these levels are
form 107 to 1010 per serving most preferred 108 to 109 per serving. Alternatively, encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 μg per serving is added, more preferably between 50 and 500 μg are added per serving. Most preferably two or three servings are given each day. - For products which are extracted to obtain the final product, generally the aim is to ensure that one serving of 200 ml or 200 grams comprises the desired amounts as indicated above. In this context, it should be appreciated that normally only part of the Lactobacillus present in the tea based product to be extracted will eventually be extracted into the final tea drink. To compensate for this effect generally it is desirable to incorporate into the products to be extracted about 2 times the amount as is desired to have in the extract.
- For leaf tea or tea-bags typically 1-5 grams of tea would be used to prepare a single serving of 200 mls.
- If tea-bags are used, the Lactobacillus may advantageously be incorporated into the tea component. However it will be appreciated that for some application it may be advantageous to separate the Lactobacillus from the tea, for example by incorporating it into a separate compartment of the tea bag or applying it onto the tea-bag paper.
- Generally dressings or mayonnaise are oil in water emulsions, the oil phase of the emulsion generally is 0 to 80 wt % of the product. For non fat reduced products the level of fat is typically from 60 to 80%, for salad dressings the level of fat is generally 10-60 wt %, more preferred 15-40 wt %, low or no fat dressings may for example contain triglyceride levels of 0, 5, 10, 15% by weight.
- Dressings and mayonnaise are generally low pH products having a preferred pH of from 2-6.
- Dressings or mayonnaise optionally may contain other ingredients such as emulsifiers (for example egg-yolk), stabilisers, acidifiers, biopolymers, bulking agents, flavours, colouring agents etc. The balance of the composition is water which could advantageously be present at a level of 0.1 to 99.9 wt %, more general 20-99 wt %, most preferred 50 to 98 wt %.
- A typical size for an average serving of dressings or mayonnaise is 30 grams. Preferred levels of Lactobacillus in such products would be 106 and 1011 per serving, more preferred these levels are from 107 to 1010 per serving most preferred 108 to 109 per serving. The Lactobacillus strain has to be added aseptically after the heating steps in the process. Alternatively, encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 μg per serving is added, more preferably between 50 and 500 μg are added per serving. Most preferably two or three servings are given each day.
- These products often comprise a matrix of edible material wherein the Lactobacillus can be incorporated. For example the matrix may be a fat based (e.g. couverture or chocolate) or may be based on bakery products (bread, dough, cookies etc) or may be based on agglomerated particles (rice, grain, nuts, raisins, fruit particles).
- A typical size for a snack or meal replacement bar could be 20 to 200 g, generally from 40 to 100 g. Preferred levels of Lactobacillus in such products would be 106 and 1011 per serving, more preferred these levels are from 107 to 1010 per serving most preferred 108 to 1010 per serving. The Lactobacillus strain has to be added aseptically after the heating steps in the process. Alternatively, encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 μg per serving is added, more preferably between 50 and 500 μg are added per serving. Most preferably two or three servings are given each day.
- Further ingredients may be added to the product such as flavouring materials, vitamins, minerals etc.
- For each of the above food products, the amount of Lactobacillus per serving has been given as a preferred example. It will be understood that alternatively any suitable probiotic micro-organism may be present at this level.
- Lactobacillus can also be used in dry powders in sachets, to be dissolved instantly in water to give a refreshing lemonade. Such a powder may have a food-based carrier, such as maltodextrin or any other. Optional further ingredients may be colourants, vitamins, minerals, preservatives, gums, thickeners etc.
- A typical size for an average serving or margarine or other spreads is 30-50 grams. Preferred VHH-producing Lactobacillus in the lemonade powder are 106 and 1011 per serving most preferred 108 to 1010 per serving. The Lactobacillus strain has to be sprayed on the carrier in such a way that it is kept alive, according to methods known by those skilled in the art. Alternatively, encapsulated VHH's may be added to these food products. Preferably between 25 and 5000 μg per serving is added, more preferably between 50 and 500 μg are added per serving.
- In all the above products the transformed micro-organism can be added as viable cultured (wet) biomass or as a dried preparation, still containing the viable micro-organisms as known in the art.
- The present invention is now further illustrated by way of the following examples.
- Rhesus rotavirus strain RRV (serotype G3) was purified, amplified and concentrated as described previously (Svensson L., Finlay B. B., Bass D., Vonbonsdorff C. H., Greenberg H. B. “Symmetrical infection on polarised human intestinal epithelial (CaCo-2) cells”. J Virol. (1991) 65, 4190-4197.
- A llama was immunized subcutaneously and intramuscularly at
day 0, 42, 63, 97 and 153 with 5×1012 pfu of rotavirus strain RRV. - Prior to immunization, the viral particles were taken up in oil emulsion (1:9 V/V, antigen in PBS: Specol (Bokhout, B. A., Van Gaalen, C., and Van Der Heijden, Ph. J. “A selected water-in-oil emulsion: composition and usefulness as an immunological adjuvant”. Vet. Immunol. Immunopath. (1981) 2: 491-500 and Bokhout, B. A., Bianchi, A. T. J., Van Der Heijden, Ph. J., Scholten, J. W. and Stok, W. “The influence of a water-in-oil emulsion on humoral immunity”. Comp. Immun. Microbiol. Infect. Dis. (1986) 9: 161-168. as described before (Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21). The immune response was followed by titration of serum samples in ELISA with RRV rotavirus coated at a titer of 4×106 pfu/ml in 0.9% NaCl following the protocol described before (De Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx P., de Bruine A. P., Arends J. W., and Hoogenboom, H. R. “A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies”. J. Biol. Chem. (1999) 274: 18218-18230.; Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21).
- An enriched lymphocyte population was obtained from the 153-day blood sample of about 150 ml via centrifugation on a Ficoll (Pharmacia) discontinuous gradient. From these cells, total RNA (between 250 and 400 ug) was isolated by acid guanidium thiocyanate extraction Chomczynski, P. and Sacchi, N. “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction”. Anal. Biochem. (1987) 162:156-159. Subsequently, first strand cDNA was synthesized using the Amersham first strand cDNA kit (RPN1266). In a 20 μl reaction mix 0.4-1 μg mRNA was used. The 6-mer random primer was used to prime the first DNA strand. After cDNA synthesis, the reaction mix was directly used for amplification by PCR. VHH genes were amplified with primers
-
Lam-16: (GAGGTBCARCTGCAGGASAGYGG); Lam-17: (GAGGTBCARCTGCAGGASTCYGG);
Lam-07 (priming to the short hinge region); and
Lam-08 (long hinge specific) - (Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21). Amplification of DNA was performed as described by De Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx P., de Bruine A. P., Arends J. W. and Hoogenboom H. R. “A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies”. J. Biol. Chem. (1999) 274: 18218-18230.
- The amplified products were digested with PstI and NotI (New England Biolabs, US) and cloned in phagemid vector pUR5071, which is based on pHEN1 (Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P. and Winter, G. “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains”. Nucleic Acids Res. (1991) 19: 4133-4137) and contains a hexahistidine tail for Immobilized Affinity Chromatography (Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. and Stither, D. “Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent”. Bio/Technol. (1988) 6:1321-1325) and a c-myc derived tag (Munro S. and Pelham H. R. “An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein”. Cell (1986) 46: 291-300) for detection. Ligation and transformation were performed as was described before (De Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx P., de Bruine A. P., Arends J. W. and Hoogenboom H. R. “A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies”. J. Biol. Chem. (1999) 274: 18218-18230.). The rescue with helperphage VCS-M13 and PEG precipitation was performed as described by Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. and Winter, G. “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991) 222: 581-597.
- Selections of rotavirus specific phages were performed via the biopanning method (Marks J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. and Winter, G. “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991) 222: 581-597.) by coating of rotavirus strain RRV (2.5×107 pfu/ml at
round 1; 5×104 pfu/ml atround 2; 500 pfu/ml at round 3). Immunotubes (Nunc, Roskilde, Denmark) were coated overnight at 4° C. with either a 1:1000 dilution of anti-rotavirus rabbit sera or anti-rotavirus guinea pig sera in carbonate buffer (16% (v/v) 0.2 M NaHCO3+9% (v/v) 0.2 M Na2CO3). Viral particles were captured via polyclonal anti-rotavirus sera. In addition to the standard selections, the antibody fragment displaying phages have selected in an acidic environment. This was done by selecting in a dilute HCl solution (pH 2.3). After this adapted selection process, the standard procedure was followed. - Soluble VHH was produced by individual E. coli TG1 clones as described by Marks J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. and Winter, G. “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991) 222: 581-597. Culture supernatants were tested in ELISA. Microlon F (Greiner Bio-One GmbH, Germany) plates were coated with 50 μl/well of a 1:1000 dilution of either anti-rotavirus rabbit polyclonal sera or anti-rotavirus guinea pig polyclonal sera in carbonate buffer (16% (v/v) 0.2 M NaHCO3+9% (v/v) 0.2 M Na2CO3) and subsequently incubated with rotavirus strain RRV or CK5 (approx. 109 pfu/ml). After incubation of the VHH containing supernatants, VHH's were detected with a mixture of the mouse anti-myc monoclonal antibody 9E10 (500 ng/ml, in-house production) and anti-mouse HRP conjugate (250 ng/ml, Dako, Denmark). Alternatively, detection was performed with anti-6×His-HRP antibody conjugate (1000 ng/ml, Roche Molecular, US). Fingerprint analysis (Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. and Winter, G. “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991) 222: 581-597) with the restriction enzyme HinFI (New England Biolabs, US) was performed on all clones. Sequencing was performed at Baseclear B.V. (Leiden, The Netherlands).
- A set of rotavirus-specific antibody fragments was selected. DNA sequences encoding these antibody fragments were isolated from pUR5071 (PstI/BstEII, New England Biolabs, US)) and cloned into pUR4547 which is identical to the previously described pUR4548 (Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21) but does not encode any C-terminal tag-sequences. This episomal yeast expression vector contains the GAL7 promoter, the SUC2 signal sequence for high level expression and secretion into the growth medium, respectively. The S. cerevisiae strain VWK18gal1 was transformed and induced for antibody fragment production as described previously (Van der Vaart, J. M., “Expression of VHH antibody fragments in Saccharomyces cerevisiae”. In Methods in Molecular Biology (2001) Vol. 178, p 359-366, Edited by P. M. O'Brien and R. Aiken, Humana Press Inc., Totowa, N.J.). Antibody fragments were purified and concentrated by filtration over microcon filters with a 10 kDa cut-off (Amicon, US).
- Total overview of anti Rotavirus VHH fragments are listed in the table below, sequences of the VHH fragments are provided in the sequence listing and
FIG. 12 . -
Yeast clone Original E. coli Episomal SEQ Ligand clone Production ID No.: Neutralization Anti-rota VHH1 2B10 +++ 1 +++ (in vivo) Anti-rota VHH2 1D3 ++ 2 ++ (in vivo) Anti-rota VHH3 1F6 ++ 3 ++ (in vivo) Anti-rota VHH4 1H4 ++ 4 ++ (in vitro) Anti-rota VHH5 GP-P3A-6E +++ 5 − Anti-rota VHH6 1B5 +++ 6 − Anti-rota VHH7 RAB-P3A-6C + 7 − Anti-rota VHH8 1B2 ++ 8 − Anti-rota VHH9 2A12 + 9 − Anti-rota VHH10 RAB-P1-2G + 10 + (in vivo) Anti-rota VHH11 1G6 +++ 11 +/− (in vitro) Anti-rota VHH12 2E4 +++ 12 ++ (in vivo) Anti-rota VHH13 2F11 ++ 13 − Anti-rota VHH14 RAB-P1-1F +++ 14 ++ (in vivo) Anti-rota VHH15 1B8 + 15 +/− (in vitro) Anti-rota VHH16 3E7 +++ 16 − Anti-rota VHH17 1D2 ++ 17 +++ (in vitro) Anti-rota VHH18 1E4 +++ 18 + (in vitro) Anti-rota VHH19 1D4 +/− 19 ++ (in vitro) Anti-rota VHH20 1A1 + 20 ++ (in vitro) Anti-rota VHH21 1E1 ++++ 21 − - Bovine Rotavirus Compton CK5 was obtained from the Moredun Institute, Midlothian, Scotland and the BS-C1 cells were purchased from the European Animal Cell Culture Collection.
- The BS-C1 cells were cultured in Earles Modified Essential Medium supplemented with 10% Heat inactivated foetal calf serum, 1% MEM Amino Acids solution (100×), 20 mmol l-1 L-Glutamine, 100 I.U. ml-1 penicillin, 100 μg ml-1 streptomycin and 2.5 μg ml-1 amphotericin B (all from Sigma, US).
- CK5 Rotavirus stock was diluted in Serum Free Medium (SFM) EMEM supplemented with 1% MEM Amino Acids solution (100×), 20 mmol l-1 L-Glutamine and 0.54 ml crystalline trypsin and then 5 ml of diluted seed was added to confluent monolayers of BS-C1 cells in 162 cm2 tissue culture flasks (Costar, UK). The virus was adsorbed onto the cells for one hour at 37° C. then the medium was topped up to 75 ml. The bottles were incubated at 37° C. until complete cytopathic effect was observed. Cultures were frozen (−70° C.) and thawed twice, then pooled and centrifuged at 1450 g for 15 minutes at 4° C. to remove cell debris. The supernatant was decanted and stored in aliquots at −70° C.
- Monolayers of BS-C1 cells were cultured in 12-well tissue culture plates at 37° C. in an atmosphere of 95% air and 5% carbon dioxide. The medium was removed and replaced with SFM for at least 2 hours prior to use. The CK5 virus was diluted to give approximately 50 pfu/ml in SFM. The selected anti-rotavirus fragments were diluted in SFM and then equal volumes of virus and fragment dilution were mixed (200 μl total volume) and incubated for one hour at 37° C.
- The virus-fragment mixtures were then plated onto the monolayers of cells (three replicate wells each). The plates were incubated for one hour at 37° C. in an atmosphere of 95% air and 5% carbon dioxide. Subsequently, the virus was removed and an overlay consisting of 0.75% Sea Plaque Agarose (FMC) in EMEM containing 100 I.U. ml-1 penicillin, 100 μg ml-1 streptomycin, 2.5 μml-1 amphotericin B and 0.1 μg/ml crystalline trypsin was added. Plates were then incubated at 37° C. in an atmosphere of 95% air and 5% carbon dioxide for 4 days. After fixing and staining with 1% crystal violet in 10% formaldehyde, the agarose was removed, the wells washed with water and the plaques counted.
- From 23 clones tested according to the method describe above, nine produced antibody fragments capable of neutralising this rotavirus strain. Fragments 2B10 and 1D3 most effectively neutralised rotavirus in the plaque assays (
FIG. 1 ) -
FIG. 1 shows virus neutralisation of rotavirus CK5 determined by an in vitro plaque assay. The average neutralisation-rate from the four obtained measurements is indicated at each data-point. If there is a spread of over 10% at a data point, the two most extreme measurements are indicated (dashed bar). The tested antibody fragments were divided over 2 graphs, A and B. A's negative controls either the virus was omitted (no virus) or a non-rotavirus specific VHH was added. The non-specific VHH fragment is specific for the human pregnancy hormone hCG. Isolation of this fragment has been described (Spinelli, S., Frenken, L., Bourgeois, D., de Ron, L., Bos, W., Verrips, T., Anguille, C., Cambillau, C. and Tegoni, M. “The crystal structure of a llama heavy chain domain”. Nat. Struct. Biol. (1996) 3: 752-757; Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21). - Hence, using this method, a number of VHH fragments were identified that can inhibit rotavirus infection in an in vitro system.
- Some of the VHH fragments selected via the approach described in example 2 were used in in vivo experiments to study the efficacy of these antibody fragment in the prevention or treatment of rotavirus induced diarrhoea in mice. This model system has been frequently used for study of rotavirus infection (Ebina, T, Ohta, M, Kanamaru, Y, Yamamotoosumi, Y, Baba, K. “Passive immunisations of suckling mice and infants with bovine colostrum containing antibodies to human rotavirus”. J Med Virol. (1992) 38: 117-123).
- 14 days pregnant, rotavirus negative BALB/c mice were obtained from Möllegård, Denmark. The mice were housed individually in the animal facility at Huddinge Hospital. Approval was obtained from the local ethical committee of Karolinska Institute at Huddinge Hospital, Sweden. Normal pellet diet and water was provided ad libitum.
- In order to examine whether the fragments can inhibit infection when bound to rotavirus (RV), selected VHH fragments were premixed with titrated amounts (2×107 ffu) of RRV before it was used for infection on
day 1. - Four-day old mice pups were treated daily with VHH fragments, including day 0 (day before infection) up to and including day 4 (
FIG. 2 ) and diarrhoea was assessed. A marked reduction in occurrence of diarrhoea was observed for antibody fragment 2B10, shown inFIG. 2 . The number of pups with diarrhoea is significantly lower atday 2 in the group receiving fragment 2B10 compared to the untreated group. Moreover, atdays FIG. 2 ). No statistically significant effects of the unrelated VHH fragment RR6 (directed against azo dyes; Frenken, L. G. J., et al. “Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae”. J. Biotechnol. (2000) 78, 11-21) was found compared to the untreated group. - Additionally, the mean number of diarrhoea days per mouse pup were calculated for each treatment group as the number of diarrhoea days per pup divided by the total number of pups per treatment group. For the fragment 2B10 treated groups this was found to be significantly reduced to 0.33±0.21 days compared to 2.87±0.29 days for the untreated group.
- It is important to note that from now on in the following examples the pUR5071 derived plasmid containing the gene encoding for fragment 2B10 was named pUR655 and the encoded antibody was renamed fragment VHH1.
- Further similar experiments separate to Examples 1 to 3 were carried out as follows:
- a) Construction of Anti-Rotavirus scFv-2A10 and VHH1 Expression Vectors.
- Total RNA was extracted from an anti-rotavirus mAb 2A10 (IgA class) secreting hybridoma (Giammarioli et al. (1996) Virol. 225:97-110)). Variable region encoding sequences of both the heavy (VH) and light (VK) chains were amplified using a 5′ RACE kit (5′ RACE System for Rapid Amplification of cDNA Ends (Version 2.0, Invitrogen™ life technologies, Carlsbad, Calif.). The primers for the 5′ RACE of VH were
-
ACRACE1: 5′-CAGACTCAGGATGGGTAAC-3′, ACRACE2: 5′-CACTTGAATGATGCGCCACTGTT-3′, ACRACE3: 5′-GAGGGCTCCCAGGTGAAGAC-3′, while the primers, mkRACE1 (5′-TCATGCTGTAGGTGCTGTCT-3′), mkRACE2 (5′-TCGTTCACTGCCATCAATCT-3′) and mkRACE3 (5′-TGGATGGTGGGAAGATGGAT-3′)
were utilized to amplify the variable region of the light chain. The resulting A-tailed PCR product was cloned into a pGEMΔ-T easy vector with 3′-T overhangs and sequenced. The VH and VK sequences were fused together with a linker encoding gene (with the amino acid sequence (G4S)3). Both chains were re-amplified from the cloned 5′ RACE products using the primers ClaI-VHs (5′-TTTTATCGATGTGCAGTTGGTGGAGTCTGG-3′) and Linker-VHas (5′-CGATCCGCCACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCACCTGAGGA GACGGTGACCGTGG-3′); Linker-VKs (5′-GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACAT TGTGATGACCCAGTC-3′) and EcoRI-Vkas (5′-TTTTGAATTCTTTTATTTCCA GCCTGGTCC-3′). The resulting VH and VK PCR products were mixed together and used as a template for a fusion PCR using the primers ClaI-VHs and EcoRI-VKas. The fused PCR products were cloned into a pGEMΔ-T easy vector after addition of overhang A using Taq DNA polymerase. The fused scFv-2A10 encoding sequence was finally cut out from the plasmids using EcoRI plus ClaI and subcloned into pBluescript II SK (+) (Stratagene, La Jolla, Calif.) containing an E-tag (pBS-E-tag). - The VHH1 was amplified from pUR655 using a sense primer containing ClaI restriction site and an anti-sense primer containing EcoRI restriction site and then inserted into the pBS-E-tag vector. For generation of surface expressed antibody fragments, the scFv-2A10-E-tag and the VHH1-E-tag were excised from the pBS-E-tag vector using ClaI and XhoI restriction sites, and fused to an anchor sequence, the last 244 amino acids of the proteinase P protein of L. casei (Kruger et al, Nature Biotechnol (2002) 20:702-706), into the Lactobacillus expression vector pLP502 (
FIGS. 3A and 3C ). To generate the secreted antibody fragment, a stop codon (TAA) was inserted by PCR amplification after the E-tag and the products were inserted into pLP502 between the ClaI and XhoI restriction sites (FIGS. 3B and 3D ). The pLP502 vector contains the constitutive promoter of the lactate dehydrogenase gene (Pldh). (Pouwels et al. “Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens” Methods in Enzymology (2001) 336:369-389). Transformation into L. paracasei was performed as previously described (Kruger et al (2002) as above). - Total RNA was extracted from different lactobacilli constructs cultured to an OD600 of 0.8 (QIAGEN) and reverse transcription was performed after digesting residual DNA with RQ1 DNase (Promega). The amount of mRNA for the different antibody fragments was measured using the qPCR core kit for SYBR® green I (MedProbe, Oslo, Norway) and ABI PRISM 7000 sequence detection system (PE Applied Biosystems, Foster City, Calif.). Typical profile times used were: initial step, 95° C., 10 minutes followed by a second step, 95° C. 15 seconds and 58° C. 1 minute, 40 cycles. Pooled cDNA was used for the generation of a standard curve for 16SrRNA and the antibody insert using the primers p0 (5′
GAGAGTTTGATCCTGGCTCAG 3′) and p6 (5′CTACGGCTACCTTGTTACGA 3′) for the 16SrRNA and primers prtpsp (5′TCTTGCCAGTCGGCGAAAT 3′) and XhoI-VHH (5′CCGCTCGAGTGCGGCACGCGGTTCC 3′) for the insert. - For purification of and VHH1-secreted antibody fragments, L. paracasei containing the constructs were cultured to an OD600 of 0.8. After centrifugation, the pH of the supernatants was adjusted to 7 and filtered through a 0.45 μm filter. The secreted antibody fragments were subsequently purified according to the instructions provided in the RPAS Purification Module (Amersham-Bioscience, Little Chalfont, Buckinghamshire, UK). Dialysis overnight at 8 C was performed with a Spectra/Porμ membrane MWCO 6-8000 (Spectrum Medical Industries, Inc., Los Angeles, Calif.) against 1×PBS. The purified antibody fragments were run on a 15% SDS-poly acrylamide gel to verify the purity of the sample and the concentration of total protein was determined by the BioRad protein assay (BioRad Laboratories, Hercules, Calif.).
- L. paracasei containing the constructs 2A10-anchor, VHH1-anchor, 2A10-secreted, VHH1-secreted, irrelevant-secreted and irrelevant-anchor were cultured in MRS broth containing 3 μg/ml erythromycin to an OD600 of 0.8. The bacteria were lysed in 10 mM Tris-HCl pH 8.0 containing 10 mg/ml lysozyme at 37 C for one hour and then disrupted by sonication (6×30 s on/off cycles) with 60% duty cycle (Digital Sonifier, model 250, Branson Ultrasonics corporation, Danbury, Conn.). Debris was removed by centrifugation. The supernatants were concentrated 50× using ultrafiltration (Amicon, Beverly, Mass.). BioRad protein assay was used to determine the protein concentration as described above.
- ELISA 96 well plates were coated with rabbit anti-human rotavirus sera (1/1000). 1:100 dilution of Rhesus rotavirus stock (RRV) was used for secondary coating. After blocking, the plates were incubated with the protein extracts or concentrated supernatants. Mouse anti-E-tag antibodies (Amersham Pharmacia Biotech, Bucks, UK) or rabbit anti-llama antibodies, horse radish (HRP) conjugated goat anti-mouse antibodies or swine anti-rabbit antibodies (DAKO A/S, Glostrup, Denmark) and 3,3′,5,5′-tetramethylbenzidine substrate (TMB) were added and the absorbance was measured at 630 nm using a Vmax Microplate Reader (Molecular Devices, Sunnyvale, Calif.). All antibodies were diluted 1/1000. Purified VHH1-E-tag and monoclonal 2A10 antibodies were used as standard to determine the concentration of antibody fragments produced by the different lactobacilli transformants.
- Flow cytometry was carried out according to standard protocols using anti-E-tag antibodies and the samples were analyzed using a FACS Calibur machine (Becton Dickinson, Stockholm, Sweden).
- Results are shown in
FIG. 4 a. - For Scanning Electron Microscope (SEM) cultures of lactobacilli transformants expressing VHH1 anchored on the surface and the non-transformed L. paracasei were mixed with RRV and after incubation, fixed and added onto a poly-L-lysine coated RC58 coated slide. The slides were analyzed by SEM (JEOL JSM-820, Tokyo, Japan) at 15 kV.
- For Transmission Electron Microscope (TEM) RRV were added onto grids, dipped in supernatant (25 times concentrated) from the lactobacilli expressing secreted VHH1 or supernatant from the non-transformed L. paracasei. Subsequently mouse anti-E-tag antibody (1:1000) and 10 nm gold labelled goat anti-mouse IgG antibodies (1:1000) (Amersham Biosciences) were added. The grids were analysed by TEM (
Tecnai 10 transmission electron microscope, Fei Company, The Netherlands) at 80 KV. - Results are shown in
FIG. 4 b andFIG. 11 . - Rhesus rotavirus was cultured in MA104 cells as previously described. Plaque-purified RRV was used throughout the study. A single virus stock was produced for the entire study by infecting MA104 cells with RRV at a multiplicity of infection (MOI) of 0.1 in serum-free M199 medium (Gibco Laboratories, Grand Island, N.Y.) containing 0.5 μg of trypsin (Sigma Chemical Co., St. Louis, Mo.) per ml. When the cytopathogenic effect reached approximately 75% of the monolayer, cells were freeze-thawed twice and cell lysates were cleared by low-speed centrifugation. The virus suspension was divided into aliquots and stored at −80° C. until use. Determination of virus titers was performed by an immunoperoxidase focus reduction test. A single virus stock was produced for the entire study.
- Antibody expressing lactobacilli were further tested for inhibitory effect on rotavirus by a microneutralization assay as described previously (Giammarioli et al 1996 as above). For anchored antibody fragments, the bacteria were serially diluted in MEM media and incubated for 1 h at 37° C. with 200 ffu of trypsin-activated RRV (100 μl). At the end of incubation, bacteria were removed by centrifugation and the supernatant was used for inoculating MA104 cell monolayers grown in 96-well plates. Concentrated culture supernatants from lactobacilli secreting antibody fragments, neat or diluted in MEM, were used for incubation with RRV and inoculation of MA104 cell monolayers. The inoculated plates were incubated at 37° C. for 1 hrs, washed with MEM medium, supplied with fresh MEM medium supplemented with antibiotics (gentamycin and penicillin/streptomycin) and incubated at 37° C. in a CO2 atmosphere for 18 h. Monolayers were fixed and stained with immunoperoxidase as described (Svensson et al 1991 as above). A reduction in the number of RRV-infected cells greater than 60% with respect to the number in control wells was considered to indicate neutralization. Purified VHH1 fragments produced by lactobacilli were used as a positive control.
- Results are shown in
FIG. 5 . - All animal experiments were approved by the local ethical committee of the Karolinska Institutet at Huddinge Hospital, Sweden. Pregnant BALB/c female mice were purchased from Møllegard, Denmark. Four-day-old pups were used for the study. Pups were fed 10 μl of different treatments once a day, starting on day −1 until
day 3. Lactobacilli were administered once, one day before rotavirus challenge. Infections were made orally onday 0 using 2×107 pfu RRV in 10 μl volume. - Occurrence of diarrhoea was recorded daily until
day 4. Pups were euthanized using intra-peritoneal pentobarbital onday 5. Sections of small intestines were stabilized in RNAlater® (QIAGEN) for RNA isolation or fixed in neutral buffered formalin for histopathological analysis or resuspended in sterile PBS for the Lactobacillus survival study. Four independent experiments were conducted with various lactobodies, initially testing the dose response behaviour of the bacteria producing VHH1 anchored VHH1 fragments and subsequently testing other lactobodies at the optimal dose. Control lactobodies expressing irrelevant antibody fragments or nontransformed lactobacilli were included in each experiment. An infection only group was also included in each experiment. - To evaluate the survival of lactobacilli in the intestine of mice, pups were once fed lactobacilli expressing anchored VHH1 on day −1 and half of them were infected with RRV on
day 0. Two pups in each group were euthanized and sections of the small intestine were removed ondays - Results are shown in
FIG. 6 . - Sections of the small intestine were taken on
day 4 and perfused with 4% neutral buffered formalin and Hematoxylin and Eosin staining was performed after sectioning according to standard protocols. Individual slides were evaluated blindly for typical signs of rotavirus infection. - Total cellular RNA was isolated from small intestinal tissue and was used for Real Time analysis after digestion of residual genomic DNA using RNase free DNase®. EZ RT-PCR® core reagent kit (PE Applied Biosystems, Foster City, Calif., USA) was used for Real Time PCR. A standard curve was generated using a pet28a (+) vector with the RRV vp7 gene cloned between the NcoI and XhoI restriction sites. Rotavirus vp7 mRNA or viral genomic RNA was amplified at 58° C. (ABI 7000 cycler, Applied Biosystems) in the presence of 600 nM primers, 300 nM probe, 5 mM Mn to generate a 121 bp long amplicon. The sense primer (VP7f: 5′-CCAAGGGAAAAT GTAGCAGTAATTC-3′) (nucleotide (nt) 791-815), the antisense primer (VP7r: 5′-TGCCACCATTCTTT CCAATTAA-3′), (nt 891-912), and the probe (5′-6FAM-TAACGGCTGATCCAACCACAGCACC-TAMRA-3′ (nt 843-867) were designed based on the vp7 gene sequence of rhesus rotavirus (accession number AF295303). The lowest level of detection of the PCR is 10 viral RNA copies. The RNA samples from each animal was normalized for the internal housekeeping gene control GAPDH (Overbergh et al, (1999) Cytokine 11: 305-312). Detection of no virus or less than 10 virus genomes was defined as clearance from infection.
- Results are shown in
FIG. 7 . - Feacal samples of three animals from the groups receiving the lactobacilli expressing the VHH1 anchored fragments, non-transformed lactobacilli or a non treated group were collected at the day of termination. The samples were smeared on a Super frost coated glass slide and fixed by methanol:acetone (1:1) for 10 minutes on ice. A mouse anti-E-tag antibody (1/200) and thereafter a cy2 labelled donkey anti-mouse antibody (1/200) was added to the slides and incubated for 1 hour under humid conditions. The surface expressed VHH1 fragments were detected by fluorescence microscope.
- The diarrhoeal illness in pups was assessed on the basis of consistency of feces. Watery diarrhoea was given a
score 2 and loose stool was given ascore 1, no stool or normal stool was given ascore 0. The percentage of diarrhoea score was calculated each day. Total daywise score in a treatment group was compared to untreated group by Fisher's exact test. Severity was defined as the sum of diarrhoea score for each pup during the course of the study and duration was defined as the sum of days with diarrhoea. Both severity and duration were analysed by Kruskal Wallis and Dunn tests. -
-
TABLE 2 Duration and Severity of diarrhoea in different treatment groups. Duration (mean ± SE) P Severity (mean ± SE) P VHH1 ank (27) 1.222 ± 0.163 Vs untreated 1.667 ± 0.250 Vs untreated <0.01 <0.001 Vs irrelevant Vs irrelevant <0.05 <0.01 Untreated (30) 2.133 ± 0.104 — 3.733 ± 0.1656 — L. paracasei (17) 1.941 ± 0.200 — 2.882 ± 0.352 — Irrelevant VHH 2.118 ± 0.169 — 3.353 ± 0.283 — ank (17) VHH1 sec (10) 1.909 ± 0.162 — 2.727 ± 0.237 — 2A10 ank (10) 2.000 ± 0.258 — 2.600 ± 0.3712 — 2A10 sec (10) 2.100 ± 0.233 — 2.900 ± 0.233 — Preincubated 1.200 ± 0.249 — 1.700 ± 0.395 Vs untreated VHH1 ank (10) <0.01 Lyophilized 1.286 ± 0.285 — 1.857 ± 0.404 Vs untreated VHH1 ank (7) <0.05 -
FIG. 4 a shows the surface expression of the 2A10-scFv and VHH1 by lactobacilli was shown by flow cytometry using an anti-E-tag antibody A lower level of detection of the E-tag was observed on lactobacilli producing the 2A10 anchored fragments compared to the VHH1 anchored and irrelevant scFv and VHH control fragments expressing bacteria (data not shown). - The binding activity of the antibody fragments was analyzed by ELISA and electron microscopy. For ELISA, homogenates of 2A10-anchor- and VHH1-anchor-transformed lactobacilli and supernatant from the 2A10-secreted- and VHH1-secreted-transformed lactobacilli were tested using the E-tag for detection. Antibody fragments, VHH1-anchored, VHH1-secreted and 2A10-anchored, expressed from lactobacilli bound to plates coated with rotavirus. A higher level of binding was observed for the llama VHH1 fragments, both anchored and secreted (purified and from the supernatant). The amount of secreted 2A10 was too low to be detected by ELISA. The non-transformed L. paracasei, irrelevant antibody fragments from transformed lactobacilli expressing anchored or secreted scFv and anchored or secreted VHH did not bind to rotavirus (data not shown). The amount of antibody fragments produced by the VHH1-anchor transformants was calculated to be approximately 104 VHH1 fragments/bacteria, and 600 2A10 fragments/bacteria (intracellular and on the surface). The VHH1-secreted transformants produced approximately 1 μg/ml of VHH1 fragments in the supernatant.
-
FIGS. 4 b and 11 a show lactobacilli expressing VHH1 antibody fragments on their surface, which were incubated with rotavirus and then analyzed by SEM. The results showed binding of the virus on the bacterial surface (FIGS. 4 ba and 11 b), but not to a non-transformed L. paracasei strain (FIG. 11 b). Using TEM (negative staining), binding to the virus by llama antibody fragments from the supernatant of lactobacilli transformed with the VHH1-secreted vector could be demonstrated, whereas the non-transformed L. paracasei strain control supernatant did not bind rotavirus (data not shown). - The effect of Lactobacillus produced antibody fragments in a rotavirus neutralization assay was analysed in
FIG. 5 . The solid line of this figure represents neutralization level achieved by lactobacilli produced E-tag purified VHH1 antibody (20 μg/ml). Dotted line indicates the neutralization level of 2A10 monoclonal hybridoma supernatant (147 ng/ml). Neutralization achieved by different concentrations of VHH1 anchored lactobacilli (▪), 2A10 anchored lactobacilli () and non-transformed lactobacilli (□).FIG. 5 shows a significant dose-dependent reduction of the infection in the presence of lactobacilli expressing surface bound VHH1 or in the presence of the supernatant containing the secreted VHH1. A slight neutralizing capacity of the supernatant from non-transformed lactobacilli was also observed. The 2A10-transformed lactobacilli (secreted and anchored) were not protective even though the supernatant of the 2A10 monoclonal hybridoma cells, containing 150 ng/ml of the antibody was 95% protective. -
FIG. 6 shows the prevalence of diarrhoea in mice treated with lactobacilli expressing VHH1-anchored fragments. Surface VHH1 expressing lactobacilli significantly reduced the diarrhoea prevalence onday 2 over non transformed lactobacilli (P=0.0172). -
FIG. 7 shows that in the untreated group, histology of the duodenum and jejunum sections reveals typical signs of rotavirus infection; swelling of villus tips, vacuolization, constriction of villus bases and unpolarized nuclei within cells (a). The groups receiving L. paracasei (b) or lactobacillus expressing VHH1-anchored (c) and the uninfected (d) shows fairly normalized histology. -
FIG. 8 shows that the mean viral load in VHH1 anchored treatment group is at least 200 fold lower than untreated group. A probiotic effect of irrelevant lactobacilli controls was also seen (10 fold reduction in viral load). Clearance from virus was defined as no vp7 detection or detection of less than 10 vp7 RNA molecules. 27% animals were cleared of rotavirus in VHH1 anchored treatment group as compared to 9% in untreated group. -
FIG. 9 shows that onday 2dose 108 CFU and 109 CFU of lactobacilli expressing VHH1-anchored fragments cause significant reduction in diarrhea prevalence compared to untreated group, P<0.0001 and P=0.0024. Number of pups in each group: 7 each in 107 CFU/dose and 108 CFU/dose and 8 in 109 CFU/dose and untreated. -
FIG. 10 shows that a group where infections were made with RRV incubated with lactobacilli expressing VHH1-anchored fragments was included. Treatment in this group was continued as usual. Surface VHH1 expressing lactobacilli given in a freeze-dried form significantly reduced the diarrhea prevalence onday 2 compared to the untreated group (P=0.0317). Onday 3, there was a significant reduction in diarrhea prevalence in groups receiving preincubated VHH1-anchored expressing lactobacilli (n=7; P=0.0004), lyophilized VHH1-anchored expressing lactobacilli (n=7; P=0.0072), VHH1-anchored expressing lactobacilli (n=10; P=0.0022) in comparison to the untreated group (n=10). Disease severity, in comparison to the untreated group, was also reduced when VHH1 surface expressing Lactobacillus was administered in a freeze-dried form (n=10; P<0.01) or when infections were made with RRV preincubated with a fresh culture of these bacteria for 2 h (P<0.05). - Faecal samples of three animals from the groups receiving lactobacilli expressing the VHH1 anchored fragments, untreated group and negative control mice were collected on
day 4, the day of termination, for determination of in situ expression of the VHH1 anchored fragments. Lactobacilli expressing VHH1 could be detected using fluorescent anti-E-tag antibody in the of treated mice. No staining could be observed in the control group (data not shown). - Pups were fed lactobacilli expressing the anchored VHH1 against rotavirus once (on day 0) and half of them were subsequently infected with RRV on
day 1. Two pups in each group were sacrificed every second day and checked for the presence of Lactobacillus transformants by culturing of the intestinal content. The bacteria could be detected in the duodenum and the ileum 48 h post treatment with no difference between the rotavirus infected and uninfected groups, whereas at 96 h post treatment, no transformants could be detected (data not shown). - The therapeutic effect of the transformed lactobacilli was tested in a mouse pup model of rotavirus-induced diarrhea. Pups were orally fed lactobacilli expressing the 2A10-scFv or the VHH1 in secreted or anchored forms during five days (day −1 to 3) and infected with RRV on
day 0. Control groups included non-transformed L. paracasei and bacteria expressing an irrelevant anchored VHH antibody fragment. 108 CFU as the optimal dose for diarrhea intervention (FIG. 9 ). The surface VHH1 expressing bacteria shortened the disease duration (normal duration 1.2 days) by approximately 0.9 days (P<0.01) and by 0.7 days compared to mice treated with non-transformed L. paracasei (P<0.05). The severity of the diarrhea was also reduced from 3.7 to 1.7 in mice treated with surface VHH1 expressing lactobacilli as compared to the disease severity in untreated pups (P<0.001) and by a factor of 1.2 in comparison to pups treated with non-transformed L. paracasei (P<0.01). A minor probiotic effect by the non-transformed lactobacilli was also observed (Table 2). In addition, the diarrhea prevalence was significantly lowered both ondays FIG. 6 a). The constructs expressing the secreted or anchored 2A10 as well as the secreted VHH1 did not induce significantly higher protection than non-transformed lactobacilli (FIG. 6 a,b). Disease severity, in comparison to the untreated group, was also reduced when VHH1 surface expressing Lactobacillus was administered in a freeze dried form (P<0.01) or when infections were made with RRV preincubated with a fresh culture of these bacteria for 2 h (P<0.05) (Table 2 andFIG. 5 ). - Histological examination of proximal small intestine sections on
day 4 revealed a marked reduction of pathological changes in rotavirus infected animals treated with surface VHH1 expressing lactobacilli and in some mice, the histology was completely normalized. The histology in the group receiving no lactobacilli revealed typical signs of rotavirus infection with swelling of villus tips, constriction of villus bases, vacuolization and irregularly placed cell nuclei (FIG. 7 a,b,c,d). To assess whether there was a reduction in viral replication in the enterocytes, a real time PCR for expression of the rotavirus vp7 gene was developed. The mean viral load in animals receiving lactobacilli expressing surface bound VHH1 antibody fragments was at least 250 fold lower than in untreated mice. Lactobacilli expressing an irrelevant VHH fragment also reduced the viral vp7 load (up to 10 fold). The clearance rate was 27% in the group given lactobacilli expressing surface anchored VHH1 as compared to 9% in the untreated group (FIG. 8 ). - These experiments show the successful expression of llama derived VHH antibody fragment (VHH1) and scFv (scFv-2A10) against rotavirus both on the surface of Lactobacillus casei 393 pLZ15 and as a secreted protein. Efficacy of these recombinant lactobacilli in the treatment of rotavirus by in vitro neutralization and in an infant mouse infection model has also been demonstrated.
- A solution of 2% sodium alginate was added dropwise to a solution of 0.1 M calcium chloride, containing 1% of the VHH, resulting in the formation of calcium alginate beads (with a size of about 2 mm). The dispersion was allowed to stand for 30 min for the calcium alginate beads to settle at the bottom of the beaker. The beads were then collected with a sieve and washed once with water
- An ice cream composition was prepared having the following formulation;
-
weight % Sucrose 13.000 Skimmed Milk Powder 10.000 Butter fat 8.000 Maltodextrin 40 4.000 Monoglycerol Palmitate (MGP) 0.300 Locust Bean Gum 0.144 Carageenan L100 0.016 Flavour 0.012 Encapsulated VHH solution at a volume resulting in between 5 and 5000 microgram of VHH per serving. Water to 100 Total soluble solids; 35% by weight Ice content at −18° C.; 54% by weight - All the ice cream ingredients were mixed together using a high shear mixer for approximately 3 minutes. The water being added at a temperature of 80° C. The temperature of the water ice mix was approximately 55-65° C. after mixing.
- The mix was then homogenized (2000 psi) and passed through to a plate heat exchanger for pasteurization at 81° C. for 25 seconds. The mix was then cooled to approximately 4° C. in the plate heat exchanger prior to use.
- Alternatively, an anti-rotavirus VHH producing Lactobacillus strain can be added Instead of the encapsulated VHH solution, preferably in a concentration of 109 per serving or higher.
- The ice cream pre-mix was then frozen using a Technohoy MF 75 scraped surface heat exchanger, no overrun was introduced into the ice cream. The ice cream was extruded at a temperature of from 4.4° C. to −5.4° C. The product was then hardened in a blast freezer at −35° C., then stored at −25° C.
- A water ice solution having the following composition was prepared as follows;
-
% by weight Sucrose 25 Locust Bean Gum 0.5 Encapsulated VHH solution at a volume resulting in between 5 and 5000 microgram of VHH per serving. water to 100 Total soluble solids; 25.5% by weight Ice content at −18° C.; 62% by weight - All the water ice ingredients were mixed together using a high shear mixer for approximately 3 minutes. The water being added at a temperature of 80° C. The temperature of the water ice mix was approximately 55-65° C. after mixing.
- The mix was then homogenized (2000 psi) and passed through to a plate heat exchanger for pasteurization at 81° C. for 25 seconds. The mix was then cooled to approximately 4° C. in the plate heat exchanger prior to use.
- Instead of the encapsulated VHH solution at this moment also a anti-rotavirus VHH producing Lactobacillus strain can be added preferably in a concentration of 109 per serving or higher.
- The water ice solution was frozen in a Technohoy MF 75 scraped surface heat exchanger with an overrun (volume fraction of air) of 30%. The water ice was extruded at a temperature of from −3.8° C. to −4.5° C. The product was then hardened in a blast freezer at −35° C., and stored at −25° C.
- Spreads were made according to standard procedure as known in the art, using the compositions as given in Table 3.
-
TABLE 3 Spread compositions Amount Amount Amount Amount (wt. %) (wt. %) (wt. %) (wt. %) Component Example 1 Example 2 Example 3 Example 4 Fat blend 39.71 39.71 39.71 39.71 Bolec ZT 0.05 0.05 0.05 0.05 Hymono 8903 0.16 0.16 0.16 0.16 β-carotene 0.08 0.08 0.08 0.08 (1% in Sunflower oil) Total fat phase 40.00 40.00 40.00 40.00 Tap water up to 60 up to 60 up to 60 up to 60 Sour whey powder 0.27 0.27 0.27 0.27 NaCl 0.48 0.48 0.48 0.48 K-sorbate 0.12 0.12 0.12 0.12 Gelatin 1.10 1.10 1.10 1.10 Citric acid To pH 4.6 To pH 5.0 To pH 4.6 To pH 5.0 Xanthan gum 0.10 0.10 0.10 0.10 Calcium salt TCP C13-13 1.27 1.27 CaSO4•0.5H2O 1.74 1.74 PH waterphase set 4.6 5.0 4.6 5.0 Encapsulated VHH sol. 5-5000 5-5000 ug 5-5000 ug 5-5000 ug Total water phase To 100 To 100 To 100 To 100 Total 100.00 100.00 100.00 100.00 - Instead of the encapsulated VHH solution after the last heating step also a anti-rotavirus VHH producing Lactobacillus strain can be added aseptically, preferably in a concentration of 109 per serving or higher.
- To prepare a dressing the bacterial strain is cultured in a suitable food raw material (e.g. milk) to achieve a high density of the culture and sufficient production of the VHH. The cultured raw material is mixed with the typical ingredients of dressings (like oil, vinegar, egg yolk, salt) at a level that supports efficacy of the VHH and subjected to standard processing of mayonnaise, like mixing and homogenisation. Alternatively, the typical ingredients of dressings like oil, vinegar, egg yolk, salt are first mixed and subjected to a heat treatment and homogenisation followed by the addition of the cultured raw material. In stead of a VHH producing micro-organism, encapsulated anti-rotavirus VHH, obtained according to example 5 can be added.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/355,981 US20120141503A1 (en) | 2004-11-25 | 2012-01-23 | Heavy Chain and Domain Antibodies |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04078212.0 | 2004-11-25 | ||
EP04078212 | 2004-11-25 | ||
EP04078211.2 | 2004-11-25 | ||
EP04078211 | 2004-11-25 | ||
PCT/EP2005/011805 WO2006056306A2 (en) | 2004-11-25 | 2005-11-03 | Hydrogel polymeric conjugates of a prodrug |
US79145608A | 2008-03-07 | 2008-03-07 | |
US13/355,981 US20120141503A1 (en) | 2004-11-25 | 2012-01-23 | Heavy Chain and Domain Antibodies |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/011805 Continuation WO2006056306A2 (en) | 2004-11-25 | 2005-11-03 | Hydrogel polymeric conjugates of a prodrug |
US79145608A Continuation | 2004-11-25 | 2008-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120141503A1 true US20120141503A1 (en) | 2012-06-07 |
Family
ID=36088316
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/791,456 Expired - Fee Related US8105592B2 (en) | 2004-11-25 | 2005-11-03 | Heavy chain and single domain antibodies |
US13/355,981 Abandoned US20120141503A1 (en) | 2004-11-25 | 2012-01-23 | Heavy Chain and Domain Antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/791,456 Expired - Fee Related US8105592B2 (en) | 2004-11-25 | 2005-11-03 | Heavy chain and single domain antibodies |
Country Status (8)
Country | Link |
---|---|
US (2) | US8105592B2 (en) |
EP (1) | EP1814514A2 (en) |
CN (2) | CN101128182B (en) |
AP (1) | AP2007004019A0 (en) |
BR (1) | BRPI0516681A (en) |
IL (1) | IL182622A (en) |
MX (1) | MX2007006086A (en) |
WO (1) | WO2006056306A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10471006B2 (en) | 2017-07-06 | 2019-11-12 | Marenda Pharmaceuticals Llc | Blend compositions for oral administration as a rapidly dissolving powder and/or suspension |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2281914T3 (en) * | 1996-06-10 | 2007-10-01 | Thomas Boren | ANTIGEN OF THE ADHESINE GROUP OF HELICOBACTER PYLORI. |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
WO2007019901A1 (en) * | 2005-08-19 | 2007-02-22 | Unilever N.V. | Food products comprising probiotic micro-organisms and antibodies |
RU2440123C2 (en) * | 2005-10-06 | 2012-01-20 | Проби Аб | Lactobacillus application for treating viral infections |
JP2010513245A (en) * | 2006-12-14 | 2010-04-30 | アクトジェニックス・エヌブイ | Delivery of binding molecules to induce immune modulation |
EP2101801A1 (en) * | 2006-12-20 | 2009-09-23 | Ablynx N.V. | Oral delivery of polypeptides |
AR062123A1 (en) * | 2007-07-27 | 2008-10-15 | Inst Nac De Tecnologia Agropec | VHH MONOMERIC DOMAIN DERIVED FROM ANTI-VP6 CAMELID ANTIBODIES, DIMERIC DOMAIN, ROTAVIRUS IMMUNODETECTION METHOD, COMPOSITIONS, ROTAVIRUS INFECTION PREVENTION AND TREATMENT METHODS |
US20110123546A1 (en) * | 2008-04-18 | 2011-05-26 | Frenken Leo Gerardus J | Compositions Comprising Antibodies or Antibody Fragments |
EP2496241B1 (en) * | 2009-11-02 | 2013-08-28 | Compagnie Gervais Danone | Method for reducing gastro-intestinal inflammation using bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria |
KR102037885B1 (en) | 2010-11-23 | 2019-10-30 | 팬더릭스 인코포레이티드 | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
CN103656633A (en) * | 2012-09-10 | 2014-03-26 | 刘占良 | Food grade lactic acid bacteria active carrier Group A rotavirus vaccine and preparation method thereof |
EP2994163B1 (en) * | 2013-05-09 | 2019-08-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
US10524493B2 (en) * | 2013-09-16 | 2020-01-07 | The Johns Hopkins University | Compositions and methods for preventing or relieving symptoms of infections |
WO2015145250A2 (en) | 2014-03-27 | 2015-10-01 | Ghosh Sambuddha | Expression of a single chain antibody against salmonella in lactobacillus |
SG11201807402PA (en) * | 2016-03-31 | 2018-09-27 | Vhsquared Ltd | Compositions |
CN106075433A (en) * | 2016-06-17 | 2016-11-09 | 山西纳安生物科技有限公司 | Many targeted nanos antibody polymerization chain junctor that a kind of probiotic bacteria that can be used for treatment of cancer is expressed |
CN106267191A (en) * | 2016-09-03 | 2017-01-04 | 山西纳安生物科技有限公司 | Nano antibody biological medicament Percutaneously administrable preparation system and preparation method and application |
CN106492216A (en) * | 2016-10-28 | 2017-03-15 | 山西纳安生物科技有限公司 | Nano antibody drug-delivery preparation system and preparation method and application through exocuticle in incidence |
WO2018158335A1 (en) | 2017-02-28 | 2018-09-07 | Vib Vzw | Means and methods for oral protein delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3735777A1 (en) | 1987-10-22 | 1989-05-03 | Mueller Lierheim S A | Carrier-bound mono- or polyclonal antibody |
EP0739981A1 (en) * | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
EP0954978B1 (en) * | 1998-03-12 | 2011-11-30 | VHsquared Limited | New products comprising inactivated yeasts or moulds provided with active antibodies |
WO2000006764A1 (en) | 1998-07-30 | 2000-02-10 | Wisconsin Alumni Research Foundation | Gastrointestinal bacterial antibody factories |
WO2000065057A1 (en) * | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
DE60138333D1 (en) * | 2000-03-14 | 2009-05-28 | Unilever Nv | Variable heavy chain domains of an antibody to human nutritional lipases and their uses |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
JP2005289809A (en) * | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | Mutant heavy-chain antibody |
-
2005
- 2005-11-03 CN CN2005800403374A patent/CN101128182B/en not_active Expired - Fee Related
- 2005-11-03 AP AP2007004019A patent/AP2007004019A0/en unknown
- 2005-11-03 CN CN2011102887393A patent/CN102336832A/en active Pending
- 2005-11-03 BR BRPI0516681-0A patent/BRPI0516681A/en not_active IP Right Cessation
- 2005-11-03 US US11/791,456 patent/US8105592B2/en not_active Expired - Fee Related
- 2005-11-03 MX MX2007006086A patent/MX2007006086A/en active IP Right Grant
- 2005-11-03 EP EP05811161A patent/EP1814514A2/en not_active Withdrawn
- 2005-11-03 WO PCT/EP2005/011805 patent/WO2006056306A2/en active Application Filing
-
2007
- 2007-04-17 IL IL182622A patent/IL182622A/en not_active IP Right Cessation
-
2012
- 2012-01-23 US US13/355,981 patent/US20120141503A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10471006B2 (en) | 2017-07-06 | 2019-11-12 | Marenda Pharmaceuticals Llc | Blend compositions for oral administration as a rapidly dissolving powder and/or suspension |
US11026886B2 (en) | 2017-07-06 | 2021-06-08 | Marenda Pharmaceuticals Llc | Blend compositions for oral administration as a rapidly dissolving powder and/or suspension |
US11642312B2 (en) | 2017-07-06 | 2023-05-09 | Marenda Pharmaceuticals Llc | Blend compositions for oral administration as a rapidly dissolving powder and/or suspension |
Also Published As
Publication number | Publication date |
---|---|
CN101128182B (en) | 2011-11-16 |
MX2007006086A (en) | 2007-07-11 |
WO2006056306A2 (en) | 2006-06-01 |
EP1814514A2 (en) | 2007-08-08 |
IL182622A0 (en) | 2007-07-24 |
CN102336832A (en) | 2012-02-01 |
IL182622A (en) | 2013-07-31 |
CN101128182A (en) | 2008-02-20 |
US8105592B2 (en) | 2012-01-31 |
AP2007004019A0 (en) | 2007-06-30 |
US20080206233A1 (en) | 2008-08-28 |
WO2006056306A3 (en) | 2007-01-18 |
BRPI0516681A (en) | 2008-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8105592B2 (en) | Heavy chain and single domain antibodies | |
US20090226418A1 (en) | Food Products Comprising Probiotic Micro-Organisms and Antibodies | |
KR101233648B1 (en) | Functional composition or food containing whey protein, antibody derived from milk, or antibody | |
CN109803666A (en) | Composition and its application method including probiotics | |
US20100233162A1 (en) | LOCAL ADMINISTRATION OF CHICKEN YOLK IMMUNE GLOBULINS (IgY) TO TREAT AND PREVENT FUNGAL INFECTIONS | |
AU779789B2 (en) | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses | |
Günaydın et al. | Engineered Lactobacillus rhamnosus GG expressing IgG-binding domains of protein G: Capture of hyperimmune bovine colostrum antibodies and protection against diarrhea in a mouse pup rotavirus infection model | |
US20110123546A1 (en) | Compositions Comprising Antibodies or Antibody Fragments | |
US10524493B2 (en) | Compositions and methods for preventing or relieving symptoms of infections | |
US20100303830A1 (en) | PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK | |
da Motta et al. | Probiotics in milk and dairy foods | |
Korhonen et al. | Bovine milk immunoglobulins against microbial human diseases | |
Renuka et al. | Delivery of Probiotics in the Food Industries | |
JP2006014654A (en) | Antibody-containing food | |
JP5058169B2 (en) | Intestinal permeation inhibitor of allergen | |
WO2023212604A1 (en) | Targeted anti-sglt1 avian igy antibodies as treatment of pre-diabetes, type 2 diabetes and gestational diabetes | |
Hultberg | Lactobacilli expressing antibody fragments against pathogens | |
KR100456326B1 (en) | Manufacturing process of IgY capsule and foods containing IgY capsule that contains immunogloblin yolk | |
KR100748842B1 (en) | Methods of Manufacturing Recombinant Antibody from Hepatitis A Virus and Applications Thereof | |
Garaicoechea et al. | VHH Technology: A Potential Passive Immune Therapy to Control Rotavirus Infections in Human Infants | |
Pant | Lactobacillus based oro-mucosal therapies against rotavirus | |
JP2011178717A (en) | Allergy prophylactic agent and food containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VHSQUARED LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONCOPCO INC., D/B/A UNILEVER;REEL/FRAME:029866/0527 Effective date: 20110622 |
|
AS | Assignment |
Owner name: VHSQUARED LTD., UNITED KINGDOM Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPLICATION NUMBER 13/555981 PREVIOUSLY RECORDED ON REEL 029866 FRAME 0527. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:CONCOPCO INC., D/B/A UNILEVER;REEL/FRAME:030447/0694 Effective date: 20110622 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |